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Background: Asthma can develop at any age. During childhood, the prevalence of asthma is 
higher in boys, but after puberty it grows higher in girls. The goals of asthma treatment are to 
achieve and maintain asthma control and to reduce future risks of exacerbations. Most 
children with asthma have a mild or moderate disease. However, a small proportion have 
severe asthma. Patients with severe asthma have the largest disease burden and require more 
healthcare resources than those with mild-to-moderate asthma. In adolescence, asthma 
management involves a transition from pediatric to adult healthcare, meaning that changes in 
care and pharmacological treatment may occur. 
Aim: The overall research aim of this thesis was to characterize asthma in adolescence and 
young adulthood, with a particular focus on sex and severity, and to identify factors of 
importance for improved asthma management during the transition from pediatric to adult 
healthcare. 
Methods: All four studies in this thesis were based on the ongoing Swedish population-based 
birth cohort BAMSE (Barn/Child, Allergy, Milieu, Stockholm, Epidemiology). This birth 
cohort includes 4,089 participants, followed from infancy up to age 24 years. Information 
about symptoms and treatment related to asthma and other allergic diseases were assessed 
through repeated questionnaires. At ages 4, 8, 16 and 24 years, the participants were also 
invited to undergo a clinical examination including for example blood sampling and 
measurements of lung function, height, and weight. To address the specific aims in this 
thesis, BAMSE data were linked to data from national and regional registers for asthma-
related healthcare consumption and dispensed medications. In addition, qualitative data were 
obtained through individual interviews. 
Results: In Study I, 14% fulfilled the study definition of asthma at 16 years of age (15% 
among females vs. 13% among males, p = 0.22). Almost half had uncontrolled asthma (46%). 
In total, 24% (n = 104) of the adolescents with asthma were dispensed high daily doses of 
inhaled corticosteroids (ICS) or fixed combinations of ICS and long-acting β2-agonists within 
the preceding 18 months. This was more common among males than females (29% vs. 19%, 
p = 0.02). Moreover, 7% (n = 24) had severe asthma (6% of females vs. 7% of males, p = 
0.61). 
In Study II, four categories emerged based on the young adults’ experiences of their 
asthma healthcare: “I have to take responsibility,” “A need of being involved,” “Feeling left 
out of the system,” and “Lack of engagement.” The young adults felt they were given more 
responsibility, did not know where to turn, and had fewer follow-ups in adult healthcare. 
Further, the participants wanted healthcare providers to involve them in self-management 
already during adolescence, and felt that their asthma received insufficient attention from 
healthcare providers. 
In Study III, 8% (n = 147) had persistent asthma. Among those with persistent asthma, 
register data showed that 39% (58 of 147) had at least 1 healthcare consultation within the 4-
year period preceding their 18th birthday and 37% (55 of 147) in the 4-year period following 
that date. The mean number of healthcare consultations in the 4-year period preceding age 18 
years was 1.6, compared with 1.0 in the 4-year period after age 18 years (p = 0.02). At least 1 
dispensation of any ICS before age 18 years was found for 73% (107 of 147), compared with 
50% (74 of 147) after age 18 years. On average, the participants with persistent asthma were 
dispensed ICS 3.1 times in the 4-year period preceding age 18 years and 2.1 times in the 4-
year period after age 18 years (p < 0.01). Only 3% of the persistent subjects (5 of 147) had a 
regular dispensation of any ICS once a year during the 8-year period. 
In Study IV, a latent class analysis was performed, and a 4-class solution of asthma 
trajectories was identified: never/infrequent (n = 3,291, 80%), early-onset transient (n = 307, 
8%), adolescent-onset (n = 261, 6%), and persistent asthma (n = 230, 6%). Uncontrolled 
asthma was equally prevalent in the adolescent-onset and persistent asthma trajectory groups, 
at both 16 (42% vs. 42%, p = 0.90) and 24 years of age (54% vs. 52%, p = 0.81). The 
persistent asthma trajectory group had a higher proportion of eosinophil counts ≥ 0.3 (109 
cells/L) at 24 years of age compared with the adolescent-onset trajectory group (31% vs. 
19%, p < 0.01). 
Conclusion: Based on the results from this thesis, it could be concluded that asthma was 
common in adolescence and young adulthood, and a shift from male to female dominance 
occurred during adolescence. Further, many adolescents and young adults had few asthma-
related healthcare consultations and dispensed asthma medications. Moreover, the 
adolescents and young adults with more recent onset of disease had equal burdens of 
respiratory markers as those who had persistent symptoms.  
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Asthma is a chronic respiratory disease, categorized by variable symptoms of wheeze, chest 
tightness and/or cough, shortness of breath, and expiratory airflow limitation (1). Symptoms 
and airflow limitation vary over time and in intensity, and can be triggered by a number of 
factors, such as allergen or irritant exposure, exercise, weather change, or viral respiratory 
infections (1-5). Asthma is a heterogeneous disease with several different underlying disease 
processes, and clinical manifestations that typically vary with age. 
Figure 1 shows an overview of asthma as interpreted in this thesis regarding 
development, diagnosis, and management. 
 
 
Figure 1. An illustration of asthma and risk factors (environment, socioeconomic status, and 
heredity) for development of the disease, as well as the diagnosing and management of 
asthma. 
Illustrated for this thesis by FB Scientific Art Design 2021. 
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1.1.1 Disease development and epidemiology 
Asthma is known to be a heritable disease (6, 7), with the heritability of childhood asthma 
estimated at around 80% (7). Family history of asthma is a risk factor, and the associations 
have been found to be more pronounced for maternal than paternal asthma (8, 9). In addition, 
exposures already in utero are of importance (10). Complex diseases like asthma appear to be 
caused by a combination of genes and the environment (10). Established environmental 
factors are, e.g., second-hand tobacco smoke exposure and air pollution (1, 11). 
Socioeconomic status has been associated with risk of asthma in many studies, and reflect 
lifestyle differences in, e.g., diet, infections, and access to healthcare. Other possible risk 
factors for development of asthma have been suggested. For example, breastfeeding for 4 
months or more seems to reduce the risk of asthma in early childhood (12). Asthma continues 
to develop throughout childhood, and childhood overweight and obesity have been associated 
with the disease (13). Although having siblings at home is associated with wheezing episodes 
in early life, it is likewise associated with protection against the development of childhood 
asthma (5). Further, considerable controversy exists regarding pet ownership, and particularly 
if cat and dog exposure may be a risk factor or a protective factor for developing asthma (14). 
The so-called atopic march constitutes the progressive development of allergic 
diseases, where allergic diseases begin in early life with eczema, progress through food 
allergy, and culminate in rhinitis and asthma later in childhood (15-18). Moreover, asthma, 
eczema, and rhinitis often co-occur, and are commonly classified as allergic co-morbidities 
(19). Allergic diseases have in common that genetic and environmental factors are interlinked 
through both immunoglobulin E (IgE)-associated and non-IgE-associated mechanisms (20). 
About half of individuals with asthma have underlying IgE-associated mechanisms, and the 
other half have non-IgE-associated mechanisms. IgE-associated mechanisms are 
characterized by a hyperreactivity of the immune system to usually harmless allergens in the 
environment. Individuals who have IgE antibodies with a specificity for a certain allergen are 
said to have allergic sensitization – they are sensitized (21).  
The international differences in asthma symptom prevalence among children have 
decreased over the last decades; symptom prevalence has decreased in Western Europe, while 
it has increased in regions where it was previously low (1). In Eastern Europe, Asia, Latin 
America, and Africa, asthma symptoms continue to grow more common. The global 
prevalence of current wheeze based on a written questionnaire (“Have you had wheezing or 
whistling in your chest in the past 12 months?”) in 2000–2003 (no new worldwide data since 
2003) among 13–14-year-old children was 14.1% (22). Figure 2 is a world map showing the 
prevalence of asthma in adults by country, which appears to vary between 1 and 22% 
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worldwide (1). However, reliable comparisons of reported prevalence rates in the world may 
be difficult to make due to a lack of universally accepted definitions of asthma.  
 
 
Figure 2. World map of the prevalence of asthma in adults by country. Data based on doctor-
diagnosed asthma and/or ever treated for asthma and/or taking asthma medication in the 
preceding 2 weeks. 
Permission to reproduce Global Initiative for Asthma (GINA) materials © 2020, Global 
Initiative for Asthma, available from www.ginasthma.org, published in Fontana, WI, USA. 
 
In early childhood, prevalence of asthma is highest among boys, but after puberty, 
asthma becomes more common among females (23-26). The reasons for this are not clear, 
but one contributing factor is differences in lung and airway size; in infancy, lungs and 
airways are smaller in boys than girls (1). Other explanations for this sex shift include 
hormonal changes and sex-specific differences in environmental exposures, e.g., smoking 
(23). Another explanation involves the underdiagnosing and undertreatment in females 
compared with males.  
Predicting who will remit and who will have persistent asthma is difficult, as certain 
forms might persist from infancy into adulthood, while others are associated with high 
likelihood of remission (2, 3). Results from epidemiological studies show that family history 
of asthma and atopy, co-morbidity, lung function deficits, and infections in early life are 
associated with persistent asthma symptoms (2, 27-30). Further, mild asthma often goes into 








Rationale for Study I 
The prevalence of childhood asthma differs between populations and the observed prevalence 
may depend on the applied study design and definition (32). Therefore, in Study I, which 
was the starting point of this thesis, the focus was on asthma in the adolescence period using 
a definition of asthma based on the large European MeDALL (Mechanisms of the 
Development of ALLergy) project (33). Further, the research group characterized asthma 




1.1.2 Diagnosis and definition 
In clinical practice, asthma in children is typically diagnosed based on the history of 
respiratory symptoms, such as wheeze, chest tightness, shortness of breath, and cough, 
together with variable expiratory airflow limitation (1). There are also several standardized 
techniques used to diagnose and monitor airway disease (such as asthma), with the choice of 
technique determined by the aim of the examination and the age and ability of the patient. 
Dynamic spirometry is the most commonly used method for measuring lung function in 
clinical practice and research, in both children and adults (34). It has yet to be confirmed if 
fractional exhaled nitric oxide (FeNO) is useful in the diagnosis of asthma (1). However, 
biomarkers such as FeNO and blood eosinophils may be used as markers of eosinophilic 
airway inflammation (1, 35). FeNO and blood eosinophils (and lung function measurements) 
have been investigated and are further described in this thesis.  
In epidemiological studies, asthma is often defined based on a combination of 
symptoms, doctor’s diagnosis and medication use – reported by parents in studies of young 
children or by the participant him- or herself in studies of adolescents and adults (36).  
 
1.1.3 Phenotypes and trajectories 
One way of characterizing asthma is to divide it into phenotype, endotype, and trajectory 
(37). Broadly, a phenotype can be described as a specific clinical characteristic. Several 
phenotypes have been identified, with respect to, e.g., age at onset of asthma (childhood vs. 
adulthood), clinical factors (episodic vs. persistent), inflammatory factors (eosinophilic vs. 
non-eosinophilic), immunological factors (atopic vs. non-atopic), and severity (treatment 
needed to achieve control) (1, 5). Endotype refers to the underlying biological mechanism 
and pathogenesis, for example allergic asthma, where asthma can be associated with IgE 
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sensitization (37). A trajectory refers to the longitudinal perspective of a trait (e.g., lung 
function), a symptom (e.g., wheeze), or a phenotype (e.g., a certain asthma type). 
Previous research studying the natural history of wheezing in childhood was initially 
based on a hypothesis-based approach (38), later supplemented by hypothesis-free data-
driven approaches, such as latent class analysis (LCA) (39). A recent meta-analysis included 
thirteen cohorts from the general and at-risk populations and used latent trajectory 
methodology to identify wheeze trajectories and associated risk factors (40). Five trajectories 
were identified, but the follow-ups varied in length between 3 and 18 years, with a mean 
length of about 10 years, and the authors concluded that more studies with consistent factor 




Rationale for Study IV 
More research was needed to confirm asthma trajectory groups defined by age at onset, and 
to improve evidence on asthma trajectory-specific factors up to young adulthood. This was in 
part due to that the number of trajectories identified, and their specific patterns, varied 
somewhat between different populations and lengths of follow-up (41). Unlike most prior 
studies (40, 42-47), Study IV provided the possibility to cover a period from infancy up to 24 
years of age. By investigating trajectories using an unbiased LCA, the research group aimed 
to provide increased knowledge about asthma development that might be translated into 
better treatment approaches, personalized medicine efforts, and – ultimately – improved 




Management of asthma is based on various asthma guidelines or recommendations, with 
GINA being one (1). GINA is based on the best evidence and medical knowledge and 
practice at the time of publication (1). Further, the European Respiratory Society and the 
American Thoracic Society (ERS/ATS) make recommendations for patient care that are 
informed by systematic reviews or pragmatic evidence syntheses formulated and graded 
using the Grading of Recommendations, Assessment, Development, and Evaluation approach 
(GRADE). In this thesis, GINA and ERS/ATS are the primary references; there are also 
national guidelines developed by, e.g., the Swedish Paediatric Society (49) and the Swedish 
National Board of Health and Welfare (50), and local guidelines used in clinical practice.  
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In the delivery of asthma management, there is variation between healthcare systems, 
with specialists delivering treatment in some countries, and primary healthcare providers 
doing so in others (1). There is also variation in the quality of asthma management, services 
across asthma specialists and primary care clinicians, and adherence to guidelines (51-54).  
 
1.1.4.1 Pharmacological treatment 
Pharmacological treatment is a cornerstone in all asthma guidelines and the basic long-term 
asthma treatment includes the following medication classes: short-acting β2-agonists (SABA; 
reliever medication) and long-acting β2-agonists (LABA; to be used together with a controller 
medication), and the controller medications inhaled corticosteroids (ICS) and leukotriene 
receptor antagonists (LTRA) (36, 55). For moderate to severe asthma, other types of 
controller medications are also available. Reliever medications are used as-needed for relief 
of breakthrough symptoms (1). Controller medications are used to reduce airway 
inflammation, risk of exacerbations, and control symptoms and lung function decline. GINA 
recommend that all adolescents and adults should receive as-needed low dose ICS/formoterol 
to reduce their risk of serious exacerbations and to control symptoms, and no longer 
recommend treating with SABA alone (56).  
However, a recent study showed that only 20% of adults used their inhaler correctly 
and in a timely fashion (57). In general, adherence to asthma medications is low in all age 
groups (58, 59). Adherence is defined by the World Health Organization (WHO) as follows: 
“the extent to which a person’s behavior corresponds with agreed recommendations from 
healthcare provider” (60). Adherence to medications can further be divided into three steps: 
initiation (taking the first dose), implementation (how a patient’s actual dosage corresponds 
to the prescribed dosage), and persistence (time from initiation until interruption of treatment) 
(61-63).  
The long-term goal of asthma treatment is to achieve and maintain asthma control, 
reduce future risks of asthma exacerbations, and enable living without restrictions (1, 8, 64). 
It is therefore important to regularly monitor symptoms and response to treatment at an 
appropriate level of care. The level of asthma control is the extent to which the manifestations 
of asthma can be observed in a patient, or have been reduced or removed by treatment (1). An 
example of assessing asthma control in clinical practice is using the validated Asthma Control 
Test (ACT), which encompasses four questions on symptoms/relievers and one question on 
self-assessed level of control (65). Most asthma patients can achieve symptom control and 
minimal exacerbations with regular controller treatment, but some will not, even with 
maximal therapy (1, 55). In some patients, this is due to severe asthma, but in others it is due 
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to, e.g., comorbidities or persistent environmental exposures (1). A smaller proportion of 
patients with asthma have severe asthma (66-69). The prevalence of severe asthma is difficult 
to assess because different definitions are used, but has been estimated to be around 5–10% 
of the entire asthma population (70-72). The ERS/ATS and GINA guidelines are often used 
for classification of severe asthma (1, 73). Severe asthma is characterized by frequent and 
severe manifestations which do not respond to treatment or only respond to high doses of 
anti-inflammatory and other controller medications (69). Before the diagnosis of severe 
asthma, patients need to go through a systematic assessment (35, 74), in order to differentiate 
between “difficult-to-treat” (where poor control is related to, e.g., poor adherence or co-
morbidities), and “true severe asthma.”  
 
 
Further rationale for Study I 
Most studies to the date of planning for Study I described severity of asthma throughout 
childhood (75-79), without studying the adolescence period separately. In a healthcare 
setting, it is important to identify patients with severe and uncontrolled asthma to gain insight 
into how pharmacological treatment can be tailored and to understand how risk factors can be 
modified (80-82). Further, to capture the relevant phenotypes of children with severe asthma, 
a careful and broad clinical characterization is required (66). 
 
 
1.1.4.2 The transition from pediatric to adult healthcare 
In early childhood, management is dependent on caregivers, who have the responsibility of 
evaluating asthma symptoms, following treatment plans, and obtaining medication (83). 
School-aged children begin to gain some level of autonomy, but rely on adults for assistance. 
For adolescents, attaining self-management is one goal. Adolescence is a challenging phase 
in life, particularly when compounded with a chronic disease (73, 84, 85). Critical objectives 
during adolescence are to acquire the confidence, knowledge, and skills that are required to 
be an independent, expert adult patient (86). This process is known as a transition, here with a 
focus on the developmental transition. There are four types of transitions, and adolescents 
with a chronic disease experience three of these – developmental (moving from adolescence 
into adulthood), health/illness (going from pediatric to adult healthcare), and organizational 
(changes in leadership, changes in care environment) (87). The fourth type is “situational,” 
e.g., beginning a new job or changing jobs. In this thesis, the focus is on the transition from 
pediatric to adult healthcare, and the terms “transition” and “transfer” are used 
interchangeably, as they often are in the literature (Figure 3). In Sweden, most children with 
severe asthma and/or asthma in combination with multiple allergic diseases are treated at 
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specialized pediatric community clinics or allergy clinics at children’s hospitals (49). At 
around patient age 18 years, asthma management includes a transition from pediatric to adult 
healthcare (88). There are many definitions of this transition, such as “a purposeful, planned 
process that addresses the medical, psychosocial, and educational/vocational needs of 
adolescents and young adults with chronic physical and medical conditions as they move 
from child-centred to adult-oriented healthcare systems” (85, 89-91).  
 
 
Figure 3. An illustration of the transition from pediatric to adult healthcare. 
Illustrated for this thesis by FB Scientific Art Design 2021. 
 
In pediatrics, a patient often goes to the same physician at a specialized pediatric community 
clinics for many years, in contrast to in adult healthcare, where a patient often visit multiple 
clinics and see different physicians to meet all of their needs, which could be a barrier to 
successful transition (92). In other words, for individuals with a chronic disease like asthma, 
the transition period can be challenging (93). However, successful support during this period 
could provide patients with lifelong skills related to how to manage their asthma and thereby 
reduce the impact of the disease (86). The transition should, according to asthma guidelines, 
be a well-planned and well-executed educational and therapeutic process (86). Previous 
research has shown that the transition from pediatric to adult healthcare is often haphazard, 
e.g., when the transition has not been planned appropriately (85, 89, 94, 95). Thus, there is a 
need for improved transition and services in all settings (96).  
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Two recent systematic reviews have highlighted that a structured transition process for 
adolescents with chronic conditions results in beneficial outcomes, such as satisfaction and 
adherence with care, and improved self-care skills (97, 98). Models for the transition from 
pediatric to adult healthcare have been developed for, e.g., congenital heart disease and 
diabetes type 1 (99, 100), but so far not for the large group of adolescents with asthma. The 
care of these diseases has similarities, but also differences. Most patients with asthma are 
managed in primary care, while those with heart disease or diabetes type 1 are managed in 
specialist care. However, for young adults with asthma, there is generally no main caregiver 
taking over responsibility after age 18 years. In a previous qualitative study, this was 
described as follows by one parent to an adolescent with severe allergic disease: “Hello, 18 
years and then, you’re out. Goodbye! Then you get no more help” (101).  
 
 
Rationale for Study II 
There was limited research in the field of asthma and the transition from pediatric to adult 
healthcare and in particular on young adults’ experiences of the transition process when I 
began my research. Most qualitative studies to date when planning for Study II focused on 
the developmental transition and adolescents becoming independent (102-104). However, to 
improve the transition process, healthcare providers need to know how young adults with 




Rationale for Study III 
Adolescents with asthma have an increased risk for asthma morbidity compared with younger 
children with asthma (89). One hypothesis used in planning for Study III was that drug 
utilization and healthcare consumption were adversely affected in the transition from 
pediatric to adult healthcare. In a healthcare setting, it is important to identify patients in need 
of further management and follow-ups, to prevent disease progress and guide adolescents in 





2 Research aim 
The overall research aim of this thesis was to characterize asthma in adolescence and young 
adulthood with a particular focus on sex and severity, and to identify factors of importance 
for improved asthma management during the transition from pediatric to adult healthcare. 
 
2.1 Specific aims 
▪ To characterize asthma in adolescence, in relation to sex and severity (Study I). 
 
▪ To investigate management of adolescents and young adults with asthma during the 
transition from pediatric to adult healthcare (Studies II and III). 
 
▪ To identify and characterize trajectories of asthma from infancy to young adulthood, and 
their associations with lung function and inflammatory and respiratory markers in 




3 Material and methods 
3.1 The BAMSE birth cohort 
All four studies in this thesis were conducted within the ongoing Swedish population-based 
prospective birth cohort BAMSE (Barn/Child, Allergy, Milieu, Stockholm, Epidemiology) 
(105). The original aim of the BAMSE study was to investigate risk factors for asthma and 
other allergic diseases in childhood, and to study factors for prognosis of already established 
allergic disease in the general pediatric population. However, the scope has broadened with 
time.  
 
3.1.1 Recruitment  
The BAMSE project started in February 2004 with recruitment of new-born children from 
child health centers in four predefined areas in Stockholm: the municipalities in the northwest 
parts of the inner city, Solna, Sundbyberg, and Järfälla. The selected study areas included 
inner city, urban, and suburban districts, and represented different types of buildings and 
parental socioeconomic statuses (education and profession). Recruitment continued until 
November 1996. A community population register ensured that the parents of all infants born 
in the area during the recruitment period were contacted. Out of the 7,221 infants born during 
this period in the study areas, the parents of 477 could never be reached and 1,256 were 
actively excluded based on the exclusion criteria: the family planned to move within 1 year of 
the project start; insufficient knowledge of Swedish; the family had a seriously ill child; an 
older sibling was already included in the study (Figure 4). This left 5,488 eligible children, 
and of these, 502 declined participation, and 897 never answered the baseline questionnaire. 
The final cohort consisted of 4,089 children (49.5% girls), 75% of the eligible children, 
whose parents answered the baseline questionnaire when their children were a median age of 
two months. 
To evaluate the representativeness of the included children in the BAMSE cohort, the 
actively excluded and non-responding families (n = 1,418) were sent a short questionnaire in 
1996 with questions on details of family history of allergic disease, parental smoking, and the 
presence of furred pets in the household. The response rate to the questionnaire was 83% 
among the actively excluded and 58% among the non-responders. The results showed that 
family history of allergic disease and keeping of pets did not differ between the actively 
excluded or non-responding families compared with the included families. However, parental 
smoking was more prevalent among the actively excluded and non-responding families than 
among the included families. Thus, family history of allergic disease did not influence the 




Figure 4. Flowchart of the recruitment and follow-up periods of the BAMSE cohort. 
 
3.1.2 Questionnaires and clinical examinations 
When the children were on average 2 months of age, a baseline questionnaire was used to 
collect information on background factors such as family history of allergic disease, parental 
education, and environmental and lifestyle factors. Follow-up questionnaires were distributed 
to parents when the participants were approximately 1, 2, 4, 8, 12, and 16 years old, to collect 
information about symptoms related to asthma and allergic diseases, lifestyle factors, and 
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treatment of asthma. Follow-up response rates were 96%, 94%, 91%, 84%, 82%, and 78%, 
respectively. In addition, at approximately 12 and 16 years, participants were asked to 
complete one questionnaire themselves. Follow-up response rates were 68% and 76%, 
respectively. At 24 years, the questionnaires were distributed only to the participants; the 
follow-up response rate was 75%. From age 12 years and onwards, most of the questionnaires 
were web-based. The questions in the questionnaires were, in so far as possible, harmonized 
with the International Study of Asthma and Allergies in Childhood (ISAAC) up to the 12-
year follow-up, and thereafter with the MeDALL project (33, 106). 
At ages 4, 8, 16, and 24 years, the participants were invited to undergo a clinical 
examination including for example blood sampling (described under 3.5.4), measurements of 
lung function (3.5.5), height, and weight. The examinations were standardized and performed 
by trained nurses.  
 
3.2 National and regional registers 
To address the specific aims in this thesis, BAMSE data were linked to data from national 
and regional registers using personal identity numbers (107). A flowchart showing how 
BAMSE data from the 16- and 24-year follow-ups were linked to mandatory Swedish health 
registries between 2008–2018 is seen in Figure 5. In Study I, the research group had 
information on prescribed and dispensed asthma medications for each participant within the 
18 months preceding the 16-year follow-up (based upon individual age). In Studies II and 
IV, the research group had information on prescribed and dispensed asthma medications for 
each participant within the 18 months preceding the 24-year follow-up (based upon 
individual age). In Study III, the research group used information regarding a period of eight 
years in total: four years before and four years after age 18 years, respectively (based upon 
individual age, participants born 1994–1996). 
 
Figure 5. BAMSE data from the 16- and 24-year follow-ups linked to mandatory Swedish 
health registries between 2008–2018, with study periods for Study III. 
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3.2.1 Stockholm Regional Healthcare Data Warehouse 
In Study III, data on asthma-related healthcare consumption were obtained from the 
Stockholm Regional Healthcare Data Warehouse, VAL (108). The register is held by Region 
Stockholm. The VAL database is a mandatory register, with both public and private care 
providers legally obliged to record diagnoses and report them to the authorities, with the 
exception of a few private clinics that do not receive subsidies (109). However, these clinics 
target the adult population rather than adolescents and young adults. Further, patients have 
the right to seek healthcare anywhere in the country, irrespective of which region they live in, 
based on agreements between the regions and the Ministry of Health and Social Affairs. In 
both primary and specialist care, there are user charges for healthcare consultations in the 
form of flat-rate fees (110, 111). However, under Swedish law, an individual will never pay 
more than 1,100 SEK (€120) per year for consultations. In region Stockholm, patients under 
18 years of age are exempt from user charges (112). The VAL database includes complete 
data on all healthcare consultations in primary and specialist care, all hospitalizations and 
medical procedures, and diagnoses based on the International Statistical Classification of 
Diseases, version 10 (ICD-10) (113). For each healthcare consultation, a maximum of 15 
diagnoses based on the ICD-10 can be registered. One diagnosis is assigned as the main 
condition, while others are secondary (110). The research group identified participants with 
physician-diagnosed asthma, ICD-10 codes J45 and/or J46, as their main or secondary 
diagnosis. To assess potential underreporting or misclassification of diagnoses, a sensitivity 
analysis was performed with all ICD-10 codes J – “Diseases of the respiratory system.” With 
data linked to personal identity numbers, it was possible to follow each individual over time 
(107).  
 
3.2.2 The Swedish Prescribed Drug Register 
In all four studies in this thesis, information on dispensed asthma medications was obtained 
by linkage to the Swedish Prescribed Drug Register (SPDR) (107, 114, 115). Since July 
2005, all drugs purchased at Swedish pharmacies are registered in the SPDR. The register is 
held by the National Board of Health and Welfare. The medications included were the 
following, classified in accordance with the Anatomical Therapeutic Chemical (ATC) 
Classification System (116): short-acting β2-agonists, SABA (R03AC02 and R03AC03), 
LABA (R03AC12 and R03AC13), ICS (R03BA), fixed combinations of ICS and LABA 
(R03AK), and LTRAs (R03DC).  
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3.3 Qualitative concepts 
Qualitative methods are often used when the aim is to improve knowledge with a focus on 
new insights and understanding (117-119), which was the specific aim of Study II. Data 
collection in qualitative research is usually achieved through interviews, with either focus 
groups or individuals (119). The method of participant recruitment is important, as this 
impacts on the variety of perceptions of the specific aim. Purposive sampling, i.e., an 
“appropriate selection,” can yield a depth and width of data, which is important for internal 
validity (i.e., whether or not the study investigates what it is meant to) (118). The sample size 
in qualitative studies is often in the range 10–25 participants (117). An approximation of 
sample size is necessary for planning, while the sufficiency of the final sample size must be 
evaluated continuously during the research process (120). There are several different tools 
used to guide sample size, and a common concept in qualitative studies is “saturation,” i.e., 
the required number of participants has been reached when new empirical data start to be 
similar to previous data (121). Another concept is “information power,” which indicates that 
the more information the sample holds, the lower the number of participants that is needed 
(120). It is suggested that a sample with enough information power depends on the aim of the 
study, the sample specificity, the use of established theory, the quality of dialogue, and the 
analysis strategy. 
In Study II, a qualitative approach was used to enable the research group to address the 
specific aim. Qualitative data were obtained through individual semi-structured (also called 
in-depth) interviews, a method chosen to gain rich and varied data to cover the aim of the 
study (118, 120). All interviews were audio-recorded, conducted in Swedish and were held in 
person or by telephone (due to geographical barriers for the participant).  
An interview guide was developed based on joint discussions between the researchers 
about factors of importance for the interview, using previous knowledge as healthcare 
providers with clinical experience of asthma management (122). A preliminary interview 
guide was formulated and pilot-tested twice. The final, slightly revised, interview guide, 
supported by previous literature, centered on exploring young adults’ experiences when 
transitioning from pediatric to adult healthcare, with a focus on expectations, needs, and 
responsibilities (123). The sequencing of the open-ended questions was not the same for 
each participant, as it depended on the individual’s responses. Supplementary follow-up 




3.3.1 Approaches for analyzing qualitative data 
Depending on the aim of the study, there are various approaches for analyzing qualitative 
data (124). Common methods include: Phenomenology – describing the common meaning of 
experiences of a phenomenon for individuals. Grounded theory – developed by Strauss and 
Corbin, with a focus on a theory that explains some action, interaction, or process. 
Ethnography – studying an intact social group primarily based on long periods of 
observations. Case study – involves the study of a case within a real-world context or setting.  
In Study II, the systematic text condensation (STC) approach, in accordance with 
Malterud (121), was used. STC is based on Giorgi’s psychological phenomenological 
analysis with the ambition to develop knowledge of the informant’s experiences and 
lifeworld (121). The research group used a non-theory-driven inductive procedure, starting 
from an individual level, gathering empirical data and then drawing conclusions. STC 
presents the experiences of the participants, as expressed by the participants themselves 
(121). STC provides intersubjectivity, reflexivity, feasibility, and a responsible level of 
methodological rigor (121). The analysis involves decontextualization and 
recontextualization (varying between parts and whole) (118) based on four steps:  
Step 1, getting an overall impression of the text by reading the transcribed data and 
identifying preliminary themes. 
Step 2, identifying meaning units in the preliminary themes by sorting out the text and 
keeping relevant text. Next, labelling with codes when sorting the meaning units related to 
the preliminary themes in step 1 – decontextualization of the results.  
Step 3, sorting the codes by meaning, and further into subgroups.  
Step 4, recontextualizing data and synthesizing the essence of each meaning from 
condensation to descriptions and concepts of each category (121).  
 
3.3.2 Validating qualitative research 
There are different ways of interpreting qualitative results, and the researcher must reflect on 
their preconceptions during the process and stay as neutral as possible to achieve 
confirmability. Further, the qualitative research process is validated through established 
concepts (125). The concepts credibility, dependability and transferability have been used to 
explain various aspects of trustworthiness: in what way can I describe and review the overall 
sustainability in the study? Credibility, describes the entire data collection process; can I 
follow the entire process? Did the authors choose the “right” participants – did they use the 
correct method? Do the participants have different experiences? Are there enough 
participants in the study to highlight the problem? Dependability, how reliable are the data? 
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How are the questions worded? Are the questions adjusted over time and how reliable are 
they after adjustment? Transferability, in what way can I transfer the results to other 
groups/patients? Is there a clear description of the context, selection, and characteristics of the 
participants, the data collection, and the analysis process? 
 
3.4 Study populations 
The four studies in this thesis had different study populations, depending on the specific aims 
and inclusion criteria.  
 
The study population in Study I consisted of 3,115 adolescents (76.2% of the original 
cohort), who had answered the questionnaire at the 16-year follow-up.  
 
The study population in Study II included young adults with asthma who had experience of 
living with asthma in adolescence and in young adulthood, and was chosen using a purposive 
sampling (118). Participants were recruited in two steps, based on information from the 
follow-ups at both 16 and 24 years. At 16 years, they were to have been classified as having 
asthma (n = 437) (Table 1). In addition, they were to have been dispensed high daily doses of 
ICS as ICS separately or as fixed combinations of ICS and LABA, in the 18 months 
preceding the follow-up (n = 104). At 24 years, they were to have had current respiratory 
symptoms in the preceding 12 months. In all, 30 individuals fulfilled these criteria according 
to data reported in the questionnaires between the start of the 24-year follow-up and February 
2018. As an invitation to participate, a research nurse called the young adults fulfilling the 
above criteria and asked if the author of this thesis (M.Ö.) could contact them. M.Ö. 
thereafter contacted those who had consented. In total, 14 young adults were excluded due to 
no contact with healthcare before and after age 18 years (n = 4), not wanting to participate (n 
= 3), or not being reachable at ≥ three different timepoints (n = 7). In total, 16 young adults 
with severe asthma were included in the final analyses. 
 
Table 1. Recruitment, fulfilled criteria and study population in Study II. 
Follow-up Fulfilled criteria Number (n) 
At age 16 years 
and 
Asthma 437 
Dispensed high daily doses of ICS or ICS/LABA 104 
At age 24 years Current respiratory symptoms 30 








In Study III, the study population consisted 
of all participants who responded to the 
questionnaires and lived in the Stockholm 
region at both the 16- and 24-year follow-
ups (n = 1,808, 44.2% of the original 
cohort) (Figure 6). For analyses related to 
the clinical examinations, participants with 
a valid spirometry measurement were 
included. 
 
Figure 6. Flowchart of the study population 
(n = 1,808) and data sources for asthma-
related healthcare consumption and 







The study population in Study IV included the original BAMSE cohort of 4,089 participants. 
 
3.5 Descriptions and definitions 
As the focus in this thesis was on adolescents and young adults, it is appropriate to specify 
these terms. According to the WHO, adolescents are individuals in the 10–19-year age group, 
a phase of life between childhood and adulthood. Further, the WHO refers to “youths” as 
individuals in the 15–24-year age group, and “young people” as individuals in the age range 
10–24 years. In this thesis, the term “adolescence” refers to the time of the questionnaire at 
the 16-year follow-up, where the age range among participants was 15.7–19.0 years (mean 
age 16.6 years). The term “young adulthood” refers to the time of the questionnaire at the 








3.5.1 Background characteristics 
Background characteristics were gathered from the baseline questionnaire answered by the 
parents when the children were about 2 months of age (Table 2).  
 
Table 2. Definitions of background characteristics used in this thesis. 
Variable Definition Study 
Young maternal 
age 
Mother’s age below 25 years of age at birth of the child. I, III, 
IV 
Preterm birth Gestational age < 37 weeks. IV 
Breastfeeding 
duration 
Exclusive breastfed for ≥ 4 months. 
IV 
Older siblings Any older siblings in the household/family at the time of 
baseline questionnaire. 
IV 
Family history of 
allergic disease 
Mother and/or father with doctor’s diagnosis of asthma and 
asthma medication and/or doctor’s diagnosis of rhinitis in 
combination with reported allergy to furred pets and/or 
pollen at the time of baseline questionnaire. 
I–IV 
Furred pet at 
home 
Had a furred pet (cat, dog, and/or rodent) at home at the 




Higher education – at least university or college 





Dominant socioeconomic status for the household, 
dichotomized into blue (low) and white (high) collar 
worker. Based on the Nordic standard occupational 





Either of the parents smoked at least one cigarette per day at 





Father and/or mother born outside of Sweden. I, III, 
IV 
 
3.5.2 Definitions of asthma and asthma phenotypes 
Definitions of asthma were based on questionnaire data from all follow-ups. Age-specific 
definitions are described in Table 3. Parents reported up to the 8-year follow-up, and 
participants reported at the 12-, 16-, and 24-year follow-ups. 
Phenotypes of asthma were defined with respect to clinical parameters (persistent 
asthma), immunological parameters (allergic asthma), age at onset (hypothesis-based 
adolescent-onset and persistent asthma), response to medication (asthma control), and 
severity of disease (asthma with high daily doses of ICS, severe asthma) (Table 3).  
Four alternative variants of asthma control were included in the definition of severe 
asthma. However, the asthma control variant used in Studies I, III, and IV was based on the 
modified GINA definition (Table 3).   
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Table 3. Definitions of asthma and asthma phenotype used in this thesis. 
Variable Definition Study 
Asthma 
at age 1, 2, 4, 8, 12, 16, 
and 24 years 
Fulfilling at least two of the following three criteria: 
Symptoms of wheeze and/or breathing difficulties in the 
preceding 12 months, ever doctor’s diagnosis of asthma, 
and/or use of any asthma medication occasionally or 
regularly in the preceding 12 months. 
I–IV 




at age 16 and 24 years 
A combination of asthma and IgE sensitization to 
inhalant allergens (cat, dog, horse, and/or house-dust 
mite, timothy grass, birch, mugwort, and/or mold) at the 
16- and 24-year follow-ups. 
III 
Asthma control 
at age 16 and 24 years 
Symptoms based on the modified GINA definition (1), 
which included: at least 4 episodes of wheeze, any night-
time awakening, activity limitation, and use of a 
symptom reliever at least 2 times/week in the 12 months 
preceding the 16- and 24-year follow-ups. Having none 
of the symptoms was defined as controlled asthma; 




Asthma with high daily doses 
of ICS at age 16 and 24 years 
Dispensed at least 800 µg budesonide or equivalent  
(≥ 500 µg fluticasone), as ICS separately or as fixed 
combinations of ICS and LABA within the 18 months 
preceding the 16- and 24-year follow-ups. 
I–IV 
Severe asthma 
at age 16 and 24 years 
Based on ERS/ATS and GINA guidelines (1, 73). 
Defined as asthma with high daily doses of ICS plus 
dispensed LABA (together with ICS separately) and/or 
LTRA at least once in the 18 months preceding the 16- 
and 24-year follow-ups to prevent the asthma from 
becoming or remaining uncontrolled despite therapy. 
Uncontrolled asthma was defined as at least one of the 
following four alternatives based on symptoms in the 12 
months preceding the 16-year follow-up: (1) 
Uncontrolled asthma as defined above (modified 
GINA); (2) Taken cortisone tablets dissolved in water 
for asthma or respiratory symptoms ≥ 3 days in a row in 
the 12 months preceding the 16- or 24-year follow-ups; 
(3) Sought acute medical care because of respiratory 
symptoms in the 12 months preceding the 16- or 24-year 
follow-ups; and (4) Impaired lung function, FEV1 below 
80% of predicted, measured through spirometry at the 
16- or 24-year clinical follow-ups. 
I, III, 
IV 
Age at onset, hypothesis-based 
Adolescent-onset asthma Fulfilling the criteria for asthma at 12 or 16 years, but 
not at earlier ages. 
I Persistent asthma Fulfilling the criteria for asthma at 12 or 16 years and at 
least 1 previous occasion at earlier ages (1, 2, 4, or 8 




3.5.3 Health outcomes besides asthma 
Health outcomes besides asthma were based on questionnaire data from the follow-ups at 
approximately 4, 8, 16, and 24 years of age. Parental responses were used up to the 8-year 
follow-up, and at the 16-year follow-up, data were based on the participants’ answers when 
possible. Age-specific definitions are described in Table 4. 
 
Table 4. Definitions of health outcomes besides asthma used in this thesis. 
Variable Definition Study 
Eczema 
At age 4 years Parental report of dry skin and itchy skin rash for ≥ 2 weeks in 
specific locations (face or arm/leg extension surfaces or 
arm/leg flexures or wrist/ankle flexures) within the preceding 
12 months and/or doctor’s diagnosis of eczema after 2 years 
and up to the date of the 4-year questionnaire. IV 
At age 8 years Parental report of dry skin and itchy skin rash for ≥ 2 weeks in 
specific locations (face or arm/leg flexures or wrists/ankles or 
neck) within the preceding 12 months and/or doctor’s 
diagnosis of eczema after 4 years of age up to 8 years of age.  
At age 16 years Adolescent-reported dry skin and itchy skin rash in specific 
locations (arm/leg flexures or wrists/ankles or neck) within the 
preceding 12 months.  
II, IV 
At age 24 years Participant’s report of itchy rash in the preceding 12 months in 
combination with 3 out of 4 of the following criteria: 1) Dry 
skin in the preceding 12 months. 2) Eczema onset below age 2 
years. 3) history of flexural eczema at any follow-up. 4) 
Personal history of asthma and/or rhinitis at any follow-up 
from age 4 years. 
IV 
Rhinitis 
At age 4 years Parental report of symptoms from eyes/nose (suspected or 
evident) after exposure to furred pets or pollen (after age 2 
years) and/or doctor’s diagnosis of allergic rhinitis after 2 
years and up to the date of the 4-year questionnaire.  
IV 
At age 8 years Parental report of symptoms of sneezing, a runny or blocked 
nose, or itchy, red and watery eyes after exposure to furred pets 
or pollen (from age 4 years) and/or doctor’s diagnosis of 
allergic rhinitis from 4 years and up to the date of the 8-year 
questionnaire.  
IV 
At age 16 years Parental report of symptoms of sneezing, a runny or blocked 
nose, or itchy, red, and watery eyes after exposure to furred 
pets or pollen (preceding 12 months) and/or doctor’s diagnosis 
of allergic rhinitis from the age of 12 years up to the date of the 
16-year questionnaire. 
II, IV 
At age 24 years Participant’s report of symptoms of sneezing, a runny or 
blocked nose, or itchy, red and watery eyes after exposure to 
furred pets or pollen (preceding 12 months) and/or doctor’s 






Continuing Table 4. 
Variable Definition Study 
BMI status at age 
16 years 
Based on data from the 16-year clinical examination. 
Calculated as kg/m2 and categorized into thinness/normal 
weight or overweight/obese, based on age-specific cut-off 
values from the International Obesity Task Force (127). 
I 
Age of puberty at 
age 16 years 
Based on self-reported information from the 16-year follow-up 
on first menarche for females and voice change for males. 
IV 
Current smoking 
at age 16 years 





“> 12 episodes of breathing difficulties” and “respiratory 
symptoms following physical exertion” were based on self-




3.5.4 Blood sampling 
Blood sampling was performed at the clinical examinations at the 4-, 8-, 16-, and 24-year 
follow-ups (Figure 4). Analyses were performed of, among other things, blood serum IgE 
and the results were used in all four studies in this thesis. IgE sensitization to common 
inhalant and food allergens was analyzed using the ImmunoCAP System (Thermo 
Fisher/Phadia AB, Uppsala, Sweden) with Phadiatop® (cat, dog, horse, birch, timothy, 
mugwort, Dermatophagoides pteronyssinus/house dust mite, and Cladosporium 
herbarum/mold), and fx5® (cow’s milk, peanut, hen’s egg, wheat, soybean, and fish). In 
Study I, inhalant allergens were further categorized into indoor allergens – cat, dog, horse, 
and/or house dust mite – and outdoor allergens – timothy grass, birch, mugwort, and/or mold. 
IgE values greater than 0.35 kUA/L
 were regarded as positive. 
In Study I and IV, analyses of eosinophils and neutrophils (performed at the 
Department of Clinical Chemistry, Karolinska University Hospital, Stockholm, Sweden) 
were also used. Values for blood eosinophil cell count were regarded as high if > 0.5 (109 
cells/L), for all ages in Study I (128, 129). In Study IV, values for blood eosinophil cell 
count were regarded as above reference if ≥ 0.3 (109 cells/L), for all ages. Values for blood 
neutrophil cell count were regarded as high if > 8.0 (109 cells/L) for < age 18 years, and > 7.5 
(109 cells/L) for ≥ age 18 years in Study I. In Study IV, values for blood neutrophil cell 
count outside normal were based on the highest tertile (tertile 3) (130): > 3.9 (109 cells/L) for 





3.5.5 Lung function 
In Studies I, III, and IV, lung function measurements were performed through spirometry 
using a Jaeger MasterScreen-IOS system (Carefusion Technologies, San Diego, CA, USA) at 
the 16- and 24-year clinical follow-ups (Figure 4). All subjects performed repeated maximal 
expiratory flow volume measurements (MEFV) (131, 132). The MEFV curves were 
manually inspected and deemed acceptable if the two highest values of forced expiratory 
volume in 1 second (FEV1) and forced vital capacity (FVC) were reproducible according to 
the ERS/ATS criteria (133, 134). FEV1 refers to the maximal volume of air exhaled in the 
first second of the forced expiration (the ability to exhale quickly). FVC measures the 
maximal volume of air exhaled with maximally forced effort from a full inspiration (the size 
of the lung). The ratio between FEV1/FVC is used to define airflow obstruction and a ratio 
under 0.7 is usually used as a cut-off value in adults (1). With reversibility testing, pre- and 
post-results are compared after inhalation of a bronchodilator, and an increase in FEV1 of  
> 12% and > 200 ml from baseline is an indicator of asthma in adults. 
Global lung function initiative (GLI) reference values were used to obtain predicted 
lung function values and corresponding standard deviation scores (z-scores) (135). GLI 
reference values provide a robust reference standard to rationalize the interpretation of 
spirometry results within and between populations worldwide. With reference values, sex, 
age, height, and ethnicity can be taken into account, meaning that a predicted value or a lower 
limit of normal (LLN) for an individual can be calculated (135). The variable airflow 
obstruction/limitation was defined as a FEV1/FVC ratio below the LLN, in turn defined as the 
lower 5th percentile in the never-asthmatic population.  
 
3.5.5.1 Fractional exhaled nitric oxide 
In Studies I and IV, fractional exhaled nitric oxide (FeNO) was investigated and a value ≥ 
25 parts per billion (ppb) was deemed to indicate the presence of eosinophilic 
inflammation. FeNO was performed at an expiratory flow of 50 mL/s (FeNO50), using an 
online chemiluminescence analyzer (at the 16-year follow-up, EcoMedics Exhalyzer®, and 
at the 24-year follow-up, Circassia NIOX VERO®). The procedure was performed in 
accordance with published guidelines (131, 136).  
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3.6 Statistical analyses 
All statistical analyses in this thesis were performed using the STATA statistical software 
(release 14.2; College Station, TX, USA). The main statistical methods used in Studies I, III, 
and IV to study whether there were differences between groups were the chi-squared test 
(Fisher’s exact test when sample sizes were small, expected numbers < 5), and tests of 
proportion for categorical/dichotomous variables. The non-parametric analysis Wilcoxon 
signed-rank test was used to study differences before and after age 18 years, and the two-
sample Wilcoxon rank-sum test was used to study sex differences in Study III. McNemar’s 
test was used on paired nominal data to evaluate differences in asthma control over time in 
Study III. One-way analysis of variance (ANOVA) was used to compare means of variables 
in Study IV. P-values of < 0.05 were considered statistically significant. 
The main statistical methods used in association analyses were logistic regression for 
categorical/dichotomous outcome variables, and multinomial logistic regression was used 
when the outcome variable consisted of more than two categories. Results were expressed as 
odds ratios (ORs) with 95% confidence intervals (CIs). Linear regression was used for 
continuous outcome variables and results were expressed as mean values with 95% CI. 
Potential confounders were selected a priori from the previous literature and included in the 
regression models. Sex, co-morbidity, age at onset of asthma, lung function, and eosinophil 
count, which are described in the background section, are known to be associated with 
asthma. Socioeconomic status/parental education (which can be defined in different ways, 
e.g., based on occupation, income, and/or education) is also known to be associated with 
asthma, reflecting lifestyle differences, such as infections, obesity (BMI status), exposure to 
allergens (IgE), exposure to tobacco smoking, and access to healthcare (1). Such lifestyle 
differences are known to be separately associated with asthma.  
The logistic regression in Study I investigating the associations between sex and 
clinical characteristics on asthma control, was adjusted for sex (females vs. males), age at 
onset of asthma (persistent vs. adolescent-onset asthma), indoor or outdoor allergens (yes vs. 
no), rhinitis (yes vs. no), BMI status (overweight/obese vs. thinness/normal weight), 
adolescent’s current smoking (yes, at least occasionally vs. no), lung function (FEV1 below 
vs. above 80% of predicted), and high blood eosinophil cell count (above vs. below the 
reference 0.5 x 109 cells/L). Further, in Study I, a multinomial logistic regression 
investigating the association between age at onset of asthma and sex was adjusted for 
socioeconomic status (white vs. blue collar), parental allergic disease (yes vs. no), and 
parental smoking at baseline (yes vs. no). 
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The logistic regression in Study III investigating the association between having had 
an asthma-related healthcare consultation after age 18 years and asthma phenotype (allergic 
asthma, asthma and airflow obstruction, asthma with high daily doses of ICS, and severe 
asthma), was adjusted for sex (females vs. males) and socioeconomic status (blue vs. white 
collar worker). 
The linear regression in Study IV investigating differences between mean values of 
lung function volume, was adjusted for sex (females vs. males), height, age, and weight at the 
16- and 24-year follow-ups, respectively. 
A LCA was performed to investigate trajectories of asthma in Study IV. Data on 
current asthma were included from all follow-ups (1-, 2-, 4-, 8-, 12-, 16-, and 24-year follow-
ups). The R software (version 4.0.2) and package “depmixS4” was used. The models were 
compared for goodness-of-fit using the Bayesian information criterion (BIC) and the number 
of clusters was confirmed. A sensitivity analysis was also performed in the same way, but this 
included current asthma only up to the 16-year follow-up.  
 
3.7 A summary of the four studies in this thesis 
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3.8 Ethical considerations 
All four studies within the thesis were performed in accordance with the ethical principles of 
the Declaration of Helsinki (137). Informed consent was provided by the guardians, 
adolescents, and young adults, depending on the age at follow-up. Participants in the project 
were informed that they were free to withdraw from the study at any stage, and individual-
level data would be deleted. At the 16- and the 24-year follow-ups, the participants were 
given a gift certificate of 500 SEK for participating in the clinical examination, as 
compensation for time lost and any inconvenience. The participants have received feedback 
on test results from the clinical examinations, and if results were abnormal, advice on seeking 
an appropriate level of care.  
In Study II, a research nurse called the young adults as an invitation to participate in 
the study, and asked if the author of this thesis (M.Ö.) could contact them, to avoid making 
them feel compelled to participate. 
 
The four studies in this thesis were approved by the Regional Ethical Review Board in 
Stockholm, Sweden. Register numbers for the permits are:  
Study I:  93:189 and 2010/1474-31/3 
Study II:  93:189, 2016/1380-31/2, 2016/2475-32, and 2017/395-32 
Study III:  93:189, 2010/1474-31/3, 2016/1380-31/2, and 2016/2475-32 




4.1 Characterizing asthma in relation to sex 
To characterize asthma in adolescence, the research group first investigated the prevalence of 
asthma in Study I and found that 14.2% (n = 437) fulfilled the study definition. Asthma 
tended to be more common among females than males (15.0% vs. 13.4%, p = 0.22). Further, 
age at onset of asthma, using the hypothesis-based approach, showed that 38.1% had 
adolescent-onset asthma and 61.9% had persistent asthma. Females had adolescent-onset 
asthma more often than males (45.3% vs. 30.0%, p = 0.01). The proportion of clinical 
characteristics among males and females with asthma in adolescence was also investigated in 
Study I. The majority of the adolescents with asthma were IgE-sensitized to inhalant 
allergens (79.9% males vs. 62.6% females, p < 0.01; Figure 7). Uncontrolled asthma was 
common – 46.2% of the adolescents with asthma had an uncontrolled disease – and more 
common among females than males (51.6% vs. 40.1%, p = 0.02). Further, in Study I, 
investigations of the distribution of uncontrolled asthma among adolescents with severe 
asthma compared with those with non-severe asthma showed a higher proportion of 
uncontrolled asthma among those with severe asthma (79.2%, vs. 53.0%, p = 0.01). In Study 
III, among the participants with persistent asthma (asthma at both the 16- and 24-year follow-
ups), uncontrolled asthma was present among 57% (80 of 147) at the 16-year follow-up and 
among 72% (103 of 147) at the 24-year follow-up (p < 0.01). In the adolescent-onset and 
persistent asthma trajectory groups, based on the hypothesis-free trajectories in Study IV, 
53.7% and 52.4%, respectively, had an uncontrolled disease at 24 years of age. 
To enable comparison of asthma in adolescence and young adulthood, additional data 
were gathered to characterize asthma based on a study population that consisted of the 3,064 
young adults who answered the questionnaire at the 24-year follow-up. In total, 14.0%  
(n = 429) fulfilled the study definition of asthma, see Figure 7. Asthma was more common 
among females than males (15.5% vs. 12.3%, p = 0.01). The proportion with IgE 
sensitization to inhalant allergens was 79.2% among males and 67.2% among females, p = 
0.02. In this age group, uncontrolled asthma was common: 74.0% had an uncontrolled 





Figure 7. The proportions with asthma and the clinical characteristics among males and 
females with asthma at age 16 years (n = 437) and age 24 years (n = 429), respectively. 
 
4.2 Asthma severity categorized based on pharmacological treatment 
Investigating severity of asthma based on pharmacological treatment in Study I showed that 
a total proportion of 23.8% (n = 104) of the adolescents with asthma had been dispensed high 
daily doses of ICS or fixed combinations of ICS and LABA within the 18 months preceding 
the 16-year follow-up (Figure 8). This was more common among males than females (29.1% 
vs. 19.2%, p = 0.02). Moreover, 6.7% (n = 24) had severe asthma (6.1% females vs. 7.4% 
males, p = 0.61). 
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To gain additional data for this thesis, investigations were also performed of asthma 
severity based on pharmacological treatment in young adulthood. This was based on the 
study population encompassing 3,064 young adults. In total, 12.6% (n = 54) of the young 
adults with asthma had been dispensed high daily doses of ICS or fixed combinations of ICS 
and LABA within the 18 months preceding the 24-year follow-up. This was more common 
among females than males, although not statistically significantly (14.3% vs. 10.1%, p = 
0.19). Moreover, 3.1% (n = 12 young adults; 10 females and 2 males) fulfilled the definition 
of severe asthma. 
In Study IV, based on the hypothesis-free trajectories, it was found that severe asthma 
at 16 and 24 years of age was most prevalent in the adolescent-onset asthma trajectory group, 
albeit quite uncommon (n = 8, 4.1% at 24 years of age). 
 
4.3 Asthma trajectories 
Based on a hypothesis-free approach in Study IV, four asthma trajectories from infancy to 
young adulthood were identified. Class 1 had a predominant profile of never/infrequent 
asthma (n = 3,291, 80.4%) (Figure 9). Class 2 had a predominant profile of early-onset 
transient asthma, with debut of asthma at 1, 2, or 4 years of age, but no asthma in later years 
(n = 307, 7.5%). Class 3 had a predominant profile of adolescent-onset asthma with a debut 
of asthma after age 8 years (n = 261, 6.4%). Class 4 encompassed participants with 
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Characterizing the trajectories, the adolescent-onset asthma trajectory group was found 
to have the highest proportion of females (n = 148, 56.7%) and the persistent asthma 
trajectory group the lowest (n = 92, 40.0%). The early-onset transient asthma trajectory group 
showed the lowest proportion of participants who had been breastfed (n = 219, 73.2%). The 
highest proportion of parental smoking (n = 82, 26.7%) was seen in the same trajectory 
group. Higher proportions of having any older siblings and having a furred pet at baseline 
were also seen in the early-onset transient asthma trajectory group. In the persistent asthma 
trajectory group, 47.8% (n = 107) had a family history of allergic disease.  
Moreover, sensitization to inhalant allergens increased with age in all trajectories, 
75.0% (n = 135) of those in the adolescent-onset trajectory group and 71.3% (n = 82) of those 
in the persistent asthma trajectory group were sensitized to inhalant allergens at age 24 years. 
Further, the proportion of allergic comorbidity was highest in these trajectory groups; about 
one third had eczema at age 4 years and about two thirds had rhinitis at age 24 years. 
Sensitization to food allergens was most common in the persistent asthma trajectory group  
(n = 60, 35.3% at 4 years of age). 
A separate comparison between the adolescent-onset and persistent asthma trajectory 
groups showed that there were few statistically significant differences with respect to 
respiratory markers, such as severe asthma and asthma control, at 16 or 24 years of age. 
However, the persistent asthma trajectory group had lower mean values of FEV1 and 
FEV1/FVC compared with the adolescent-onset group, as well as a higher proportion of 
airflow limitation (18.1% and 10.3%, p = 0.05) at age 16 years, a lower mean value of FEV1, 
and a higher proportion of eosinophils (31.0% vs. 18.5%, p = 0.02) at age 24 years. Further, 
the persistent asthma trajectory group had the highest proportions of FeNO values ≥ 25 ppb at 
both 16 and 24 years of age (41.7% and 34.3%, respectively).   
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4.4 The transition from pediatric to adult healthcare 
4.4.1 Experiences 
In the qualitative analyses in Study II, important aspects of the included participants’ 
experiences of the transition from pediatric to adult healthcare were identified. In total, four 
categories emerged during the analysis process: “I have to take responsibility,” “A need of 
being involved,” “Feeling left out of the system,” and “Lack of engagement” (Figure 10). 
 
 
Figure 10. The analysis process in STC, steps 1–4. 
 
Category – “I have to take responsibility” 
After the transition to adult healthcare, the young adults expressed that they had to take more 
responsibility. They felt that they needed to be mature enough to take on full responsibility; it 
was up to the individuals to handle everything and to keep in touch with healthcare. The 
young adults’ responsibilities included requesting care and taking their own asthma seriously.  
“Just because you turn 18 and become an adult on paper, that doesn’t mean that you 










Category – “A need of being involved” 
The young adults had not been aware that a transition from pediatric to adult healthcare was 
going to occur, and they wished that the healthcare providers had involved them in the 
process. Moreover, the young adults wanted a joint preparation for adult healthcare so that 
they, as young adults, would be more prepared, which would help them understand their 
asthma management.  
“It’s good if the center provides information that we are not responsible for you 
anymore and we will be referring you on, so that it’s not just a final check-up and you 
leave and think that you’ll be going back there again.” (# 6) 
 
Category – “Feeling left out of the system” 
The information about the transition had been lacking, and the young adults did not know 
where to turn for, e.g., a renewed prescription, and what the next step was. Moreover, they 
experienced fewer follow-ups than before, or none at all, whether or not a transition had 
occurred. Also, in the pediatric asthma/allergy clinic, the young adults had been familiar with 
their healthcare providers, but this was no longer the case after the transition, and visits 
became impersonal.  
“It was really easy when I had a pediatrician. I just went there or called and they’d say 
that I could come in and then I could just barge in there and… So that was really easy. 
I got to know him. Now it’s like okay, where should I go, what do I do, who do I call 
and so on. So that part is a bit more difficult now.” (# 4) 
 
Category – “Lack of engagement” 
The visits tended to come to nothing in adult healthcare, partly because they were often 
focused on a renewed prescription and no discussion or evaluation of the treatment; therefore, 
the visits did not feel important. Moreover, the young adults felt that their asthma in general 
received insufficient support from healthcare providers, compared with other chronic 
diseases. They felt that asthma was underestimated, and this feeling increased with time. For 
their part, the young adults viewed their asthma as something that affected their way of life 
during their most formative years and that had a big impact on them.  
“Asthma is something that affects your way of life, in a way, during your most 
important formative years. It has quite a big impact.” (# 8)  
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4.4.2 Asthma-related healthcare consultations 
Asthma-related healthcare consultations during the transition from pediatric to adult 
healthcare were investigated in Study III. In total, the study covered an 8-year period, 
extending 4 years before and 4 years after age 18 years. This period is hereafter denoted 
“before and after age 18 years.” During the 4 years before age 18 years, 39% (58/147) of the 
young adults with persistent asthma (8.1%, n = 147; current asthma at both the 16- and 24-
year follow-ups) had ≥ 1 asthma-related healthcare consultation; similar to the figure of 37% 
(55/147) for the 4-year period after age 18 years. Only 2% (3/147) had yearly healthcare 
consultations during the entire study period of eight years. The mean number of consultations 
decreased from 1.6 before age 18 years to 1.0 after age 18 years (p = 0.02). 
Figure 11 shows the number of healthcare consultations before and after age 18 years, 
respectively, among participants with persistent asthma, divided by level of care. The most 
common combination was having no healthcare consultation either before or after age 18 
years, and the second most common was attending specialist care before age 18 years, but 
having no healthcare consultation after age 18 years. After age 18 years, the mean number of 





Figure 11. Number of healthcare consultations during the 4 years before and after age 18 
years, respectively, divided by level of care, among young adults with persistent asthma  
(n = 147).  
aHealthcare consultations in both primary and specialist care were merged into specialist care 
(n = 4). 
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Figure 12 shows the prevalence of current asthma among the participants with persistent 
asthma, and the mean number of yearly healthcare consultations in relation to sex.  
 
 
Figure 12. The mean number of yearly consultations among young females (n = 79) and 
males (n = 68) with persistent asthma and the prevalence of asthma during this period. The 
prevalence of current asthma is plotted based on prevalence at the 12-, 16-, and 24-year 
follow-ups. 
 
Males had a higher mean number of healthcare consultations before age 18 years (males: 2.1, 
females: 1.2, p = 0.25), but after age 18 years, no difference was seen (males: 0.9, females: 
1.1, p = 0.90). In regard to the registered healthcare consultations, medical procedures were 
also investigated; the mean number of registered spirometry tests among the participants with 
persistent asthma decreased from 0.27 before age 18 years to 0.16 after age 18 years (p < 
0.01). More than 1 spirometry was registered among 27% (40 of 147) of the young adults 
before age 18 years and among 16% (24 of 147) after age 18 years. 
 
4.4.3 Asthma-related pharmacological dispensation 
Asthma-related pharmacological dispensation during the transition from pediatric to adult 
healthcare was investigated in Study III (in total, an 8-year period extending 4 years before 
and 4 years after age 18 years, respectively). Results showed that among those who fulfilled 
the criteria for persistent asthma (8.1%, n = 147; current asthma at both the 16- and 24-year 
follow-ups), at least one dispensation of reliever medication (SABA) was found for 70% 
(103/147) before age 18 years compared with for 50% (73/147) after age 18 years. The 
average number of dispensations was 2.8 before age 18 years and 2.1 after age 18 years (p < 
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0.01). Only 3% (4/147) had a regular dispensation of SABA once a year during the entire 
study period of eight years. As regards controller medication, at least one dispensation of any 
ICS (including ICS and fixed combinations of ICS and LABA) was found for 73% (107/147) 
before age 18 years, compared with for 50% (74/147) after age 18 years. The mean number 
of dispensations of any ICS was 3.1 before age 18 years and 2.1 after age 18 years (p < 0.01). 
During the entire eight-year period, only 3% (5/147) had a regular dispensation of any ICS 




5.1 Main findings and interpretations 
5.1.1 Asthma prevalence and characteristics 
Asthma during childhood is a broad term. This thesis has provided up-to-date results on the 
prevalence of asthma in the transitional period between childhood and adulthood within the 
general population. The asthma prevalence rates were assessed using standardized methods 
and required the presence of self-reported symptoms during a set period (the preceding year 
at each follow-up), as many asthmatics have intermittent symptoms and may not have them 
on the day of study (138). As regards asthma characteristics, the results of Study I showed a 
higher proportion of females than males with defined asthma at age 16 years, which 
highlights the natural course of asthma and is a clear manifestation of the “sex shift” in 
asthma prevalence (23). In Study IV, the adolescent-onset asthma trajectory group had the 
highest proportion of females, also highlighting the sex difference in age at onset of disease 
(139, 140). The results showed that uncontrolled asthma was more common among females 
than among males in adolescence and young adulthood. It has been proposed that asthma is 
underdiagnosed, undertreated, and more severe among females, and the later onset may lead 
to it not being properly identified in healthcare (23, 141). Study III also indicated potential 
undertreatment among females, as it was found that males had a higher mean number of 
healthcare consultations before age 18 years, though no difference between sexes was seen 
after age 18 years. Further support could be seen in that females had a higher proportion of 
severe asthma than males in young adulthood. These aspects need to be considered by 
healthcare workers who diagnose and treat individuals with asthma. 
In a healthcare setting, it is important that adequate diagnostic tools are being used to 
identify asthma patients. However, a previous Swedish cross-sectional study of children in 
primary healthcare centers showed that only 22% of children aged 6 years and older with an 
asthma diagnosis had ever undergone a spirometry test (142). In Study III, the number of 
registered spirometry tests was also very low, with one or more spirometry registered among 
only 16% of the participants with persistent asthma during the 4-year period after age 18 
years. A previous study showed that not having had lung function testing at the time of initial 
diagnosis of asthma was associated with failure to have current asthma confirmed (143). The 
asthma diagnosis should be confirmed, to avoid unnecessary or overtreatment or missing 
other diagnoses (1). Moreover, a single low measure of lung function measured with 
spirometry may not represent a true estimate of an individual’s later risk of obstructive 
disease (34). On the other hand, repeated low measurements may indicate persistent reduction 
or rapid decline in lung function over time, which are more likely to be associated with an 
 
40 
increased risk of chronic obstructive pulmonary disease in early adulthood. It is therefore 
important that adolescents and young adults with asthma have regular follow-up visits, even 
if their asthma is mild (144). Study III showed that registered healthcare consultations were 
fewer than recommended in international and Swedish guidelines. 
 
5.1.2 Asthma phenotypes and trajectories 
In Studies I, III, and IV, several asthma phenotypes and trajectories were identified and 
characterized. Through identification and characterization of asthma phenotypes and 
trajectories, asthma management can be individualized and made multidisciplinary, to ensure 
the best outcomes (145). In Study IV, a hypothesis-free approach was used. The results were 
in line with those of other studies, which have identified similar classes to describe childhood 
asthma trajectories (40). The unbiased studies have often identified 3 to 5 trajectory groups. 
The variations in the number of identified trajectories may be explained by differences in 
study populations, sample size, asthma definitions, or frequency and timing of data collection 
(42). 
When the trajectories in Study IV were characterized, established background factors 
were seen to be associated with the trajectories of age at onset of asthma. For example, family 
history of allergic disease was associated with a persistent wheeze trajectory in childhood (2). 
Moreover, higher proportions of parental smoking at baseline seemed to characterize the 
early-onset transient asthma trajectory (40). Factors such as “being breastfed,” “having an 
older sibling,” and “having a furred pet” at baseline also characterized the early-onset 
transient asthma trajectory. Results from a previous Prevention and Incidence of Asthma and 
Mite Allergy (PIAMA) study showed that having older siblings in the first year of life 
increased the risk of transient early wheeze (146). On the other hand, a previous study 
observed a reduced risk of intermediate-onset wheeze (appearing at around 18 months) for 
those who had a dog in the household at baseline and for first-born children (147). However, 
a previous study found little evidence of the association between wheeze trajectories and pet 
ownership (148). Moreover, results from a previous study pooling 11 European birth cohorts 
together found that pet ownership in the first 2 years of life did not increase or reduce the risk 
of asthma in children aged 6–10 years (14). Further, most participants with early allergic co-
morbidity belonged to the adolescent-onset and persistent asthma trajectory groups. In the 
same trajectory groups, about one third had eczema and were sensitized to food allergens at 
early ages. Positive IgE sensitization to inhalant allergens increased with age in all 
trajectories, following the concept of the atopic march (16, 17, 149). Sensitization to allergens 
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is thought to have an important role in the development of asthma (15). Despite some overlap 
with other asthma trajectories, allergic asthma may be classified as its own distinct trajectory.  
In the separate comparison between the adolescent-onset and persistent asthma 
trajectory groups in Study IV, the results showed that these groups seemed to have equal 
burdens of respiratory markers, such as severity of disease and impaired asthma control, in 
adolescence and young adulthood, even though the adolescent-onset trajectory group had a 
more recent onset of disease. However, the persistent asthma trajectory group, with the 
highest proportions of high FeNO and high eosinophil counts, had more signs of type-2 
inflammation (150) than the adolescent-onset trajectory group. Further, the persistent asthma 
trajectory group had lower mean values of FEV1 and FEV1/FVC, and a higher proportion of 
airflow limitation in adolescence. These results were in line with a previous study showing 
that asthma patients with increased FeNO and eosinophil counts had a higher prevalence of 
impaired lung function and uncontrolled asthma compared with patients with normal levels of 
these inflammatory markers (128). 
 
5.1.3 Management of adolescents and young adults with asthma in relation to 
guidelines 
The long-term goal of asthma management is to achieve control of symptoms through, e.g., 
treatment (1, 8, 64). ICS can control asthma by optimizing lung function and reducing 
symptoms and disease burden (1, 58). Despite this, almost half of the adolescents with 
asthma in Study I and about two thirds of the young adults with persistent asthma in Study 
III had an uncontrolled disease. Adherence to ICS is poor, leaving patients exposed to the 
risks of SABA-only treatment (151, 152). In the new GINA guideline recommendations, 
treatment of asthma with SABA alone is no longer suggested for adults and adolescents (56). 
This underlines the importance of increased understanding of asthma and asthma 
management (153).  
Basic asthma management requires self-management education, optimization of inhaler 
technique and treatment adherence, and avoidance of environmental triggers (1, 82). 
Adolescents and young adults with asthma are often treated in primary care, and ideally in a 
team with a registered nurse (154). Primary care nurses can make significant contributions to 
improve health outcomes for patients with a chronic disease (155). Written action plans for 
managing worsening symptoms and structured education provided by asthma nurses are 
prioritized actions in the Swedish National Board of Health and Welfare’s guidelines (50). 
Self-management is an important factor in asthma control, and results from a recent Swedish 
study showed that knowledge of self-management procedures among adults with asthma was 
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associated with a written action plan, advanced treatment, higher educational level, physician 
continuity, and, in females, visiting an asthma nurse (156). In contrast, the participants in 
Study II expressed a feeling of impersonal contact and experienced a lack of engagement in 
adult healthcare. This was also found in a recent systematic review of qualitative studies 
exploring people’s experiences of living with severe asthma (157). People with severe asthma 
try to achieve a greater level of personal control over their condition, but they receive lacking 
support from their healthcare providers. This highlights the importance of bridging the gap in 
asthma management among adolescents and young adults (Figure 13). 
Adherence to ICS is an important part of asthma management throughout life, and may 
be especially challenging during the transition into adulthood (58). Low numbers of 
dispensed asthma medications were seen for all asthma phenotypes in Study III. Moreover, 
during the study period of eight years, almost no one was dispensed asthma medications 
regularly. The overall rate of optimal adherence to asthma medications is generally low 
(between 22 and 63%), and adolescents with asthma typically report poorer adherence than 
children and adults (58, 59). A recent systematic review found that the prevalence of 
adherence to ICS was 28% in young adults (mean age between 15 and 30 years) (58). This 
may be due to the increase in self-management in medication and other self-care 
responsibilities that occurs during adolescence. Previous studies have also shown that 
children’s dispensing patterns of asthma medications are affected by siblings, as they may 
share asthma medications (108, 158). Socioeconomic status also impacts on dispensation; 
when assessing the effect of an eliminated patient fee on asthma medications, the volume 
dispensed per child increased for families with a low socioeconomic status. Moreover, a 
recent systematic review found two factors significantly associated with adherence among 
adult patients with severe/“difficult-to-treat” asthma: male sex and a better asthma-related 
quality of life score (159). Further, sex is known to affect the dispensing patterns of asthma 
medications in children, including adherence to controller medication (higher among boys) 
(160). A difference in dispensing patterns in relation to sex was also seen in Study I. Males 
had been dispensed high daily doses of ICS or fixed combinations of ICS and LABA more 
than females (this also correlated with the higher mean number of consultations before age 18 
years among males in Study III). The additional data from the 24-year follow-up showed the 
same results, although the difference was not statistically significant, indicated that females 
are undertreated and underdiagnosed (23).  
Furthermore, using the definition of severe asthma in this thesis, partly based on the 
requirement to fulfil criteria for asthma and dispensations of high daily doses of ICS, a 
smaller group among the participants with asthma was found to have severe asthma. 
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However, the prevalence was in line with a previous Swedish population-based study (70). 
The definition of severe asthma is not unambiguous, and establishment of an improved 
definition – including risk assessment and a reflection of the clinical reality – has been 
suggested (161). Moreover, the prevalence and the characteristics of patients with “severe 
asthma” most likely differ depending on region, climate, healthcare system, and reporting 
(161). Prior to 2000, there were no consensus definition of “severe asthma” (162). In 2014, a 
joint task force, supported by the ERS/ATS, provided recommendations and guidelines in 
children and adults on the evaluation and treatment of severe asthma (73). In 2018, the ERS 
Severe Heterogeneous Asthma Research collaboration, Patient-centered (SHARP) Clinical 
Research Collaboration (CRC) was set up to harmonize severe asthma management across 
Europe and deal with the underlying heterogeneity (163). In a recent study from the SHARP 
CRC, the group highlighted a need for agreement between ERS/ATS and GINA guidelines, 
as the differences in definitions could be confusing for physicians (161). Ideally, an 
international consensus should be reached on a set of key variables that can be collected in 
national registries to increase their usability.  
 
Figure 13. An illustration of bridging the gap in asthma management among adolescents and 
young adults. 




5.1.3.1 The transition from pediatric to adult healthcare 
A chronic disease like asthma may cause deterioration among patients in adolescence, prior 
to or following the transition to adult healthcare (164). In Study III, uncontrolled asthma 
among the participants with persistent asthma (asthma at both the 16- and 24-year follow-
ups) increased significantly following the transition to adult healthcare. In Study IV, about 
half of the patients in the adolescent-onset and persistent asthma trajectory groups had a 
uncontrolled disease at 24 years of age. More than a tenth in the persistent asthma trajectory 
group had airflow limitation and more than a third had a high eosinophil count at 24 years of 
age.  
However, there is guidance for clinicians on the transition from pediatric to adult 
healthcare (88). To support the transitional care of adolescents and young adults with asthma, 
the European Academy of Allergy and Clinical Immunology (EAACI) recently developed a 
clinical practice guideline to provide evidence-based recommendations for healthcare 
providers (86). Further research is needed to assess whether transition guidelines are used and 
have a long-term impact on care (90). Healthcare providers’ adherence to transition 
guidelines appeared to be inadequate, based on the results in Studies II and III. In Study II, 
some of the young adults did not know a transition should occur when they were around 18 
years of age. System barriers, such as not receiving information on the transition, have been 
identified in earlier studies, emphasizing the need for better communication between pediatric 
and adult healthcare during the transition process (165, 166). In Study III, registered 
healthcare consultations were fewer than recommended in international and Swedish 
guidelines for all asthma phenotypes (1, 49, 50), and their frequency decreased after the 
transition. Regarding level of care, the mean number of healthcare consultations to specialist 
care was found to decrease after age 18 years, while the number of visits to primary care 
increased. Given that Swedish primary care is responsible for providing basic medical 
treatment, the result was as expected (167). However, most of the participants attending 
specialist care before age 18 years had no healthcare consultation either in primary or 
specialist care after age 18 years. To ensure continuity, patients who are managed well in 
primary care can remain there, but the majority of adolescents with asthma requiring a 
tertiary level of care would be expected to need specialist care as adults (144). A recent U.S. 
study investigated clinician-reported adherence to asthma guideline recommendations, and 
found that agreement with and adherence to guidelines was higher among specialty 
physicians than among primary care physicians. It also found overall low adherence with, 
e.g., use of written action plans and medical procedures (52). Based on the literature and 
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results from this thesis, it can be concluded that there is a gap between asthma guidelines and 
actual management (88, 93, 96, 98, 123, 165, 168, 169). 
Teamwork between the pediatric and adult systems is key to improving communication 
and coordination in the transition from pediatric to adult healthcare (88). Team-based care in 
both the pediatric and adult settings could increase the chances of success. The basics of 
transition, common to all diseases and conditions, are to prepare young adults in advance for 
moving to adult healthcare, to prepare adult services to receive the young adults, and to listen 
to the young adults’ own ideas of what they want from the transition (88, 170). The focus is 
often on children, and healthcare relies on parents reporting asthma symptoms, but responses 
in adolescence and young adulthood are not the same, with adolescents and young adults 
expected to be independent patients and to self-manage their asthma (83). A recent doctoral 
thesis investigating patient empowerment during the transition to adulthood in young persons 
with chronic conditions discussed the importance for young people to be empowered and to 
feel capable of asking questions and participating in the healthcare process (87). Developing 
their communication skills will facilitate their participation in adult healthcare once they are 
transferred. Further, the results showed that in young persons with a congenital heart disease, 
patient empowerment was correlated with transition readiness. Moreover, a previous 
published qualitative meta-synthesis of adolescents’ and young adults’ experiences of the 
transition from pediatric to adult hospital care showed that this was more than a change from 
one place to another (123). It is known that these experiences are linked into a pattern of 
developmental, health-illness, organizational, and situational transition issues. The authors 
also identified feelings of not belonging, similar to those among the young adults in Study II, 
and the needs among young adults to be acknowledged as competent during the transition 
process, across chronic diagnoses. 
 
5.2 Methodological considerations 
5.2.1 Random errors 
Epidemiological studies may be afflicted by two types of error: random or systematic errors 
(5.2.2) (171). Random errors originate from the sampling variability. Sample size is a source 
of random errors, and to reduce sampling errors one way is to enlarge the size of the study 
(172). The CI indicates the amount of statistical variability: a wide CI implies low precision 
and a narrow CI implies high precision (171). Due to the limited number of subjects with, 
e.g., high blood eosinophil cell count and severe asthma, it could be difficult to draw 
conclusions like those drawn in Study I, where a wide CI was seen for high blood eosinophil 
cell count when investigating “sex and clinical characteristics in relation to uncontrolled 
 
46 
asthma among adolescents with asthma at age 16 years.” In Study III, when investigating 
“asthma phenotypes at the 16-year follow-up in relation to one consultation after age 18 years 
among young adults with persistent asthma,” the wide CI of severe asthma indicated a 
statistical uncertainty. However, this was a population-based study; participants with high 
blood eosinophil cell count and severe asthma were expected to be fewer than in selected 
patient populations. 
 
5.2.2 Systematic errors 
In contrast to random errors, systematic errors do not depend on the study size or chance. A 
study can be biased because of how the participants have been selected (selection bias) or 
how the variables have been measured (information bias), or because of some confounding 
factor that is not completely controlled (171). Selection bias, information bias, and 
confounding are the most common systematic errors. 
 
5.2.2.1 Selection bias 
In this thesis, selection bias might have occurred from the procedures used to select 
participants during the recruitment of the BAMSE cohort, the study populations, and when 
participants were loss to follow-up (171).  
During the recruitment of the BAMSE cohort, 477 families could never be reached and 
1,256 were actively excluded due to that the family planned to move within 1 year of the 
project start, had insufficient knowledge of Swedish, had a seriously ill child, or an older 
sibling was already included in the study (Figure 4) (105). The short questionnaire to 
evaluate the representativeness of the included children in the BAMSE cohort and the 
excluded and non-responding families showed that there were no major differences regarding 
family history of allergic disease and other known risk factors for allergic disease – except for 
parental smoking, which was more prevalent among the excluded and non-responding 
families than among the included families. Since comparisons in this thesis have been made 
within the cohort, non-participation in the baseline questionnaire has most likely not 
introduced bias in the observed associations between the exposure and outcome.  
Selection bias may occur in longitudinal studies due to loss to follow-up. The BAMSE 
cohort has a low rate of loss to follow-up (at age 16 years, 76% of the participants completed 
the questionnaire, and at age 24 years, 75%), comparable to the 72% response rate at age 20 
years in the German Multicentre Allergy Study (MAS) birth cohort study (173). A low rate of 
loss to follow-up reduces the risk of selection bias.  
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To evaluate possible selection bias, Studies I and III included comparisons of the 
characteristics of the study populations and those of the original BAMSE cohort, showing 
minor differences. The statistically significant differences for parental allergic disease, higher 
parental education, and female sex most likely did not affect the observed associations. Still, 
selection bias cannot be ruled out. For example, participants with a history of allergic disease 
have remained in the BAMSE cohort more often than those without a history of allergic 
disease, which might lead to an overestimation of asthma prevalence.  
 
5.2.2.2 Information bias 
Information bias can occur if the collected information about or from the study participants is 
incorrect (171). Such information is often referred to as misclassification. Misclassification 
can be non-differential or differential. Non-differential misclassification is distributed equally 
in relation to the exposure or outcome, leading to a dilution of the association (171). 
Differential misclassification is not equally distributed in relation to the exposure and 
outcome, which can cause an over- or underestimation of the association.  
There are reports of under- and over-diagnosis of asthma in children (138, 174). In this 
thesis, definitions of asthma were based on questionnaire reports of validated and widely used 
questions (33, 106). A recent study investigating the agreement of parental responses to 
asthma‐related questions regarding their children and Swedish healthcare registers found 
good agreement (175). This indicates that questionnaires are appropriate proxies for asthma 
in general and can be used for healthcare research. However, in this thesis, the definitions of 
asthma were based on parent-reported data up to 8 years of age, and on the participants’ 
answers from age 12 years. In the BAMSE project, a previous study based on the 12-year 
follow-up examined whether there was a difference between children and parents in reporting 
symptoms and treatment of allergic diseases and found that the children reported more 
symptoms than their parents, whereas questions about pharmacological treatment had high 
levels of agreement (176). However, some misclassification is difficult to avoid, as people 
may interpret questions differently or may not remember accurately. 
In the LCA in Study IV, longitudinal data were used, with the same definition of 
asthma from infancy up to young adulthood. At infancy (at 1 and 2 years of age), this 
definition of asthma (i.e., fulfilling at least two of the following three criteria: symptoms of 
wheeze and/or breathing difficulties in the preceding 12 months, ever doctor’s diagnosis of 
asthma and/or asthma medication occasionally or regularly in the preceding 12 months) was 
somewhat more stringent than the definition of, e.g., the Swedish Pediatric Society (49). 
Accordingly, asthma in children (non-IgE-mediated or in combination with eczema, food 
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allergy or family history of allergic disease) before the age of three years, was diagnosed after 
three episodes of wheeze. After three years of age, an asthma diagnosis could be made after 
one episode, or before that if the child had IgE-mediated asthma or in combination with 
eczema, food allergy or family history of allergic disease, and/or repeated episodes in 
between. The non-differential misclassification may have caused an underestimation of 
asthma at 1 and 2 years of age in Study IV. There is no gold standard in defining asthma 
during childhood, and there is a trade-off in between using a strict definition, and missing 
cases (high specificity – the proportion of participants without the disease, who have a 
negative result of the test/symptom – but low sensitivity – the proportion of participants with 
the disease who also have a positive result of the test/symptom (171)) and using an inclusive 
definition and classifying cases as non-cases (high sensitivity, but low specificity).  
Other potential sources of misclassification are the modified GINA definition of asthma 
control, which was based on information for the 12 months preceding each questionnaire; the 
GINA guidelines base asthma control on information from the last 4 weeks (1). The non-
differential misclassification may have led to an overestimation of the proportion of 
adolescents and young adults with uncontrolled asthma in the studies included in this thesis. 
Moreover, an overestimation of the prevalence of severe asthma in Studies I, III, and IV 
may be present, due to the participants not undergoing a systematic assessment to 
differentiate “severe asthma” from “difficult-to-treat” patients, in whom poor control is 
related to factors such as poor adherence or co-morbidities (35). Also, the cut-off values of 
the treatment with “high” daily dose of ICS or fixed combinations of ICS and LABA differ 
between studies. In this thesis, GINA’s suggested “high” dose was used (1). The 
misclassified participants would be equally distributed in relation to the exposure and 
outcome, which would imply a non-differential misclassification. 
The risk of misclassification is lower for objectively collected data. The examinations 
of blood sampling, lung function, and height and weight were standardized and performed by 
trained nurses. However, different cut-off values were used for blood eosinophils: > 0.5 (109 
cells/L) in Study I and > 0.3 (109 cells/L) in Study IV. Both are widely used in literature (35, 
129). For neutrophils, different cut-off values were also used. However, in a recent study, it 
has been discussed that the level of blood neutrophils does not accurately predict airway 
neutrophils and that neutrophilic airway inflammation can only be assessed by induced 
sputum (35). In this population-based cohort, sputum analyses of neutrophils have not been 
performed. Further, it has been suggested that a FeNO > 50 ppb indicates eosinophilic airway 
inflammation and responsiveness to corticosteroids (in this thesis defined as ≥ 25 ppb), and 
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that a value of 25–50 ppb should be interpreted carefully with reference to the clinical context 
(177).  
Information gathered via healthcare registers has many strengths, but may theoretically 
have limitations. When using the national VAL register in Study III, a sensitivity analysis 
with wider ICD-10 codes was performed to assess potential underreporting or 
misclassification of diagnoses. This showed comparable results, indicating a small potential 
of non-differential misclassification in asthma diagnoses. Moreover, as patients have the right 
to seek healthcare anywhere in Sweden, irrespective of which region they live in, a non-
differential misclassification of the number of healthcare consultations in Study III may be 
present, as it is common for young adults to move from their hometown due to studies in 
another city. To minimize the risk of non-differential misclassification, the study population 
was restricted to include only participants who lived in the Stockholm region at both the 16- 
and the 24-year follow-ups. 
Moreover, a previous study validated asthma diagnoses in the regional SPDR and 
suggested that asthma medication in the SPDR could be used as proxy for asthma (178). In 
gathering information on dispensed asthma medicines via the SPDR, my coresearchers and I 
used an 18-month window, based on information from a previous study comparing the 
concordance between register data and dispensed medicines and parental/self-reported use of 
asthma medicines in adolescents (179). The study found that the best general agreement with 
the questionnaires was the 18-month time window (the different time windows were: 3, 6, 12, 
18, and 24 months prior to the respective questionnaires). The highest concordance between 
the register and reported use was seen for adolescents with severe asthma. Moreover, when 
investigating dispensed asthma medicines in registers, it is important to consider irregularities 
in purchasing asthma medicines due to the variability in the disease over time.  
 
5.2.2.3 Confounding 
In general, a confounder must be associated with both the exposure and the outcome, and it 
occurs when the association between the exposure and outcome is attributable to another 
exposure (a third factor) (172). Confounding indicates that the effect of the exposure is mixed 
with the effect of another variable, meaning that the association is due to another factor than 
the investigated exposure, leading to a bias (171). The confounding factor can cause a 
decreased or an increased association. There are three methods to prevent confounding: 
randomization, restriction, and matching (171). To control for confounding in the analysis, 
two methods can be used: stratification and regression models (171). However, the influence 
of unmeasured and unknown confounders cannot be ruled out in any non-randomized trials. 
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The BAMSE study’s prospective design and extensive information on background and 
allergy-related symptoms allowed evaluation of potentially confounding factors. In Studies I 
and III, a hypothesis was that sex could be a confounding factor when investigating 
adolescents and young adults with asthma in relation to uncontrolled disease, adolescent-
onset asthma, and healthcare consultations. To control for sex, analyses were therefore 
stratified and adjusted for sex (among other things). Additional data in this thesis – asthma 
control, asthma with high daily doses of ICS, and severe asthma at age 24 years – were also 
stratified for sex. Logistic regression models were used in Studies I and III and tested for 
confounding. Factors were included in the adjusted model based on a priori knowledge. 
Although a number of variables were considered to be potential confounders in this thesis, 
residual confounding (factors that are not controlled for or factors that are controlled for, but 
measured inaccurately) may have been present (171).  
 
5.2.3 Generalizability 
Generalizability, or external validity, is the degree to which the results of an observation can 
be applied in other settings (180). This thesis was based on the BAMSE study – with a 
population-based design and a large and well-characterized study sample. In the final cohort 
consisting of 75% of the eligible children, parental smoking was more prevalent among the 
actively excluded and the non-responding families than among the included families. 
However, history of allergic disease did not influence the motivation to participate, thus it 
may be assumed that the results in this thesis can be generalized to other similar populations 
in urban-industrial settings. The prevalence of asthma and the asthma phenotypes 
corresponded well with those seen in other Swedish (30, 70, 181, 182), Nordic (72, 183), and 
European studies (184). 
The results were based on the Swedish population and the generalizability to other 
countries may be discussed for Study III, since healthcare systems vary between countries; 
modes of payment, the uses of specialist services, and reimbursement systems also vary 
(110). However, the transition from pediatric to adult healthcare is an international concern, 
and the results can most likely be transferred to other countries and populations. 
 
5.2.4 Strengths 
The strengths of Studies I, III and IV (quantitative) in this thesis included the population-
based prospective design, the high participation rate, the repeated assessments of allergic 
diseases, and the combination of clinical objective data such as IgE sensitization, lung 
function, and height and weight. Another strength was the use of register data through linkage 
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to mandatory Swedish health registries, with high quality and coverage. The national SPDR 
provided complete data on the number of individuals exposed to dispensed prescribed 
medications in the Swedish population (114). The regional VAL database has approximately 
85% coverage of all diagnoses in primary care, more than 90% coverage of utilization in 
specialist care, and more than 99% coverage of hospital care (185). 
 
5.3 Methodological considerations in relation to qualitative research 
In Study II, the STC approach was used to analyze qualitative data. The procedures of STC 
are simple and accessible for novices, although with limited room for creative interpretations 
and elegant conclusions (121). The detailed descriptions of the procedures for analysis with 
STC support transparency and intersubjectivity, as the procedures are easy to conduct and 
present. However, a range of methods can be applied in qualitative analysis, and a transparent 
description of the path from data to results is necessary to convey to the reader what was done 
(118). In Study II, there are various aspects of trustworthiness. To show confirmability, the 
researchers reflected on their preunderstanding of having different experiences of the specific 
aim being investigated and the method being used (186, 187). Further, in recruitment, the sex 
aspect was kept in mind, to uncover potential differences in perceptions since sex differences 
have been revealed, e.g., girls are less likely to achieve asthma control than boys (115). 
However, socioeconomic status was not taken in account, which could be associated with 
certain experiences of the transition process. Through the purposive sampling, credibility may 
have been achieved thanks to the varied selection of participants which provided multiple 
perspective of the phenomena in relation to the specific aim (125). The sample also promoted 
credibility as the participants gave sufficient variety to highlight the purpose (117, 187). The 
sample size was based on “information power” and factors having an impact were the quality 
of dialogue, the relevant and purposive sample, the narrow aim, and the chosen analysis 
strategy (120). 
Individual interviews were performed, but a group context could have been used 
instead. The advantage with focus groups, for example, is the interaction in a group context 
which can result in a broader perspective, as participants are more likely to express their 
opinions after listening to others in a similar situation (117, 186). Moreover, the interviews 
with open-ended questions were based on an interview guide. Using an interview guide 
strengthens the dependability of a study. Other advantages are that it helps the researcher to 
focus on different perspective of the phenomenon that they are investigating and that all the 
participants are given the same questions (125, 186). In this case, it also saved time due to the 
dross rate being lower than in unstructured interviews (186). When the interviews were 
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performed, the participants had a mean age of 23.4 years (range 22.4–24.5). This means that 
the participants were likely to remember what it was like 4–6 years earlier, when they should 
have transferred from pediatric to adult healthcare. This could be a disadvantage, which 
might have been solved by using another way of recruiting the participants, e.g., adolescents 
who were in the midst of the transition, i.e., 18 years of age at the time of the interviews. 
However, in general, participants tell their story from their perspective, even if their 
memories are selective. The accuracy of the interview data is not as important as the 
motivations and thoughts of the participants (186). Through descriptions of when in time the 
data were collected, the reader gets a clue to the stability as well as the dependability in the 
collected material over time.  
To achieve credibility in the analytical process, all steps were first conducted by the 
author of this thesis and then separately by the co-authors of the respective studies. The 
authors discussed their results jointly, until they reached agreement (125). Researchers 
triangulate to corroborating evidence to validate the accuracy of a study (124). Credibility 
also deals with how to assess similarities within and differences between categories (125). A 
way of approaching this is to show representative quotations from the transcribed text. 
Results of qualitative studies cannot be generalized, but can be transferred to other 
settings and groups (188). However, Study II can be argued to add new knowledge through 
the participants’ various experiences of the transition process, which can promote reflection 
among healthcare providers on how to manage the transition from pediatric to adult 
healthcare.  
A non-theory-driven inductive procedure was used in the analysis of the material in 
Study II. Thus, no theoretical framework was used; in STC, the role of theoretical frames of 
reference for analysis can be applied in different ways. A range of theories can be applied to 
support STC analysis, depending on the specific research question of a study (121). Theories 
can be used to frame a research question, guide the selection and interpretation of data, and as 
a basis for explanations of the causes underlying observed phenomena (189). However, the 
purpose and impact of theoretical perspectives are regularly debated in qualitative research. 
There is considerable variation regarding theoretical commitment; some prefer studies 
without a hint of theory, others prefer those where empirical findings disappear among 




Based on the results from this thesis, it could be concluded that asthma was common in 
adolescence and young adulthood, and a shift from male to female dominance occurred 
during adolescence. Further, many adolescents and young adults had few asthma-related 
healthcare consultations and dispensed asthma medications. Moreover, the adolescents and 
young adults with more recent onset of disease had equal burdens of respiratory markers as 
those who had persistent symptoms. 
 
The following specific conclusions could be drawn from Studies I-IV: 
 
▪ About half of the adolescents with asthma had an uncontrolled disease, which was more 
common among females. Morover, females more often had adolescent-onset asthma than 
males. Although this is quite uncommon, some of the adolescents with asthma have 
severe asthma. 
 
▪ Asthma-related healthcare consumption and pharmacological dispensations were fewer 
than recommended and decreased after the transition from pediatric to adult healthcare. 
Further, based on the young adults experiences’ of the transition, participants felt that 
they did not know where to turn within adult healthcare, and they wanted healthcare 
providers to involve them in self-management already during adolescence. 
 
▪ Using a hypothesis-free approach, four asthma trajectory groups were identified from 
infancy to young adulthood, as were their associations with lung function and 
inflammatory and respiratory markers in adolescence and young adulthood. The 
adolescent-onset and persistent asthma trajectory groups had equal burdens of asthma 
control and severity in adolescence and young adulthood. However, the persistent asthma 
trajectory group showed more signs of type-2 inflammation than the adolescent-onset 
trajectory group.  
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6.1 Clinical implications 
Studies I-IV have the following clinical implications: 
 
▪ The results highlighted the clinical relevance of monitoring the treatment of asthma in 
adolescents and young adults, especially among patients with uncontrolled and severe 
asthma, and in females. 
 
▪ The results highlighted that healthcare providers should increase their understanding of 
the difficulties that young adults with asthma face during the transition from pediatric to 
adult healthcare. It is suggested that healthcare providers work together with each patient 
to prepare, plan, and communicate in the progressive transition process, to acheive 
continued care in line with current guidelines. 
 
▪ The results showed that there was a need for healthcare providers to be aware of and 
identify patients in adolescent-onset and persistent asthma trajectory groups, in order to 




7 Points of perspectives 
As a continuation of my research for this thesis, and the overarching aim to make significant 
contributions to the knowledge base regarding how the management of adolescents and 
young adults with asthma can be improved, I would like to further explore and advocate 
future research. 
 
▪ Asthma management – hospital-based material 
This thesis is population-based, however it would also be interesting to investigate e.g., the 
prevalence of severe asthma including a systematic assessment and differentiate “severe 
asthma” from “difficult-to-treat” in patients treated at specialized allergy clinics. 
 
▪ Parents perspective of the transition process – a qualitative study 
This thesis produced less knowledge about the parents perspective of the transition from 
pediatric to adult healthcare, therefore to gain further knowledge regarding their experiences 
of the management during the transition process it would be of great intrerest to e.g. perform 
focus group interviews.  
 
▪ Impact of the disease in young adulthood – a cross-sectional study 
In the BAMSE cohort, health-related quality of life (HRQoL) has previously been 
investigated using the generic instrument EQ-5D (190). At age 8 and 16 years, children with 
asthma had a lower median EQ visual analogue scale value than children without asthma 
(191, 192). In adolescence, the impairment was most pronounced if asthma was uncontrolled 
(192). Previous studies has shown that adolescent males with asthma report better HRQoL 
than female peers (26, 193-195). It would be interesting to compare HRQoL in young adults 
with asthma, as they now have become independent adult patients. Also, the influence of the 




8 Popular science summary of the thesis 
Asthma is one of the most common chronic diseases during childhood. The goal of asthma 
treatment is to achieve and maintain asthma control and to reduce future risks of 
exacerbations. With asthma medication and support for self-care, this should be possible to 
achieve for the vast majority of patients. However, this is not always the case, particularly 
among adolescents and young adults. Adolescents and young adults thus have an increased 
risk of uncontrolled asthma compared with younger children. Children with more severe 
asthma are typically treated in children’s hospitals, but a transfer to adult healthcare is carried 
out when they are around 18 years old. One hypothesis is that the young person loses contact 
with healthcare during this period. The overall aim of this thesis was to characterize asthma in 
adolescence and young adulthood with a particular focus on sex and severity, and to identify 
factors of importance for improved asthma management during the transition from pediatric 
to adult healthcare. 
All four studies in this thesis were based on the ongoing Swedish BAMSE (Barn/Child, 
Allergy, Milieu, Stockholm, Epidemiology) study. The BAMSE study included 4,089 
participants born between 1994–1996. The participants have been followed since infancy 
with regular follow-ups, including questionnaires and clinical examinations; the latest follow-
up was when the participants reached age 22–24 years.  
Study I investigated how many of the participants who had asthma during adolescence, 
in relation to sex and severity of disease. Overall, it was found that asthma in adolescence 
was common (14%), and a small group of adolescents had severe asthma, although this was 
quite rare. Females had asthma more often than males. About half of the adolescents with 
asthma had an uncontrolled disease. This was more common among females. 
Study II examined young adults with severe asthma and their experiences of the 
transition from pediatric to adult healthcare. Individual interviews provided a deeper insight 
and revealed weaknesses in the transfer process, as the young adults felt that they did not 
know where to turn and experienced fewer follow-ups in adult healthcare. Further, the young 
adults wanted the caregivers to involve them in self-care during adolescence. In general, they 
felt that their asthma received insufficient attention from the caregivers. 
Study III investigated the care of adolescents and young adults during the transition 
from pediatric to adult healthcare. To do this, information was gathered from Swedish 
registers of asthma-related dispensed medicines and healthcare contacts. The results showed 
that the healthcare contacts were fewer than recommended and decreased after the transfer to 




Study IV identified different types of asthma from infancy to young adulthood and 
patient groups were characterized based on, among other things, asthma control and severity 
of disease. Those who had a late debut and those who had persistent asthma were found to 
have a similar burden of asthma control and severity during adolescence and young 
adulthood. 
In summary, the results suggested that asthma was common among adolescents and 
young adults. About half had uncontrolled asthma during adolescence; this was more 
common in females than males. Through identification and characterization of different types 
of asthma, management and treatment can be individualized. Due to the shortcomings in the 
transition from pediatric to adult healthcare, where management is not carried out in 
accordance with guidelines for asthma, it is an important task for healthcare to identify the 




9 Svensk populärvetenskaplig sammanfattning 
Astma är en av de vanligaste kroniska sjukdomarna under barndomen. Målet med 
astmabehandling är normal lungfunktion och att kunna leva ett gott liv utan begränsningar i 
dagliga aktiviteter, med så få symtom som möjligt. Med astmamediciner och stöd till 
egenvård bör det kunna uppnås för det stora flertalet. Dock är så inte alltid fallet och speciellt 
stort är problemet bland ungdomar och unga vuxna. Ungdomar och unga vuxna har därmed 
en ökad risk för okontrollerad astma jämfört med yngre barn. Barn med svårare astma 
behandlas och följs vanligen på barnsjukhusen, men när ungdomarna är kring 18 år ska en 
överföring till vuxensjukvården genomföras. En hypotes är att den unga personen tappar 
kontakten med sjukvården under den här perioden. Det övergripande syftet med den här 
avhandlingen var att undersöka astma hos ungdomar och unga vuxna med ett särskilt fokus 
på kön och astmans svårighetsgrad samt att urskilja viktiga faktorer för förbättrat 
omhändertagande under överföring mellan barn- och vuxensjukvård. 
Samtliga fyra delstudier i den här avhandlingen baserades på den pågående svenska 
BAMSE (Barn, Allergi, Miljö, Stockholm, Epidemiologi)-studien. BAMSE-studien 
inkluderade 4,089 barn födda mellan 1994 och 1996. Deltagarna har följts sedan 
spädbarnsåren med regelbundna uppföljningar i form av frågeformulär och kliniska 
undersökningar och den senaste uppföljningen var när deltagarna nått 22–24 års ålder. 
I delstudie I undersöktes hur många som hade astma i tonåren i relation till kön samt 
astmans svårighetsgrad. Resultaten visade att astma i tonåren var vanligt (14%), men att få 
ungdomar hade en svår astma. Kvinnor hade oftare astma än män. Ungefär hälften av 
ungdomarna med astma har en okontrollerad sjukdom, vilket var vanligare bland kvinnorna. 
I delstudie II undersöktes unga vuxna med svårare astma och deras erfarenheter av 
överföringen från barn- till vuxensjukvård. Individuella intervjuer gav en djupare inblick och 
avslöjade brister i överföringsprocessen, då de unga vuxna upplevde att de inte visste vart de 
skulle vända sig och upplevde färre uppföljningar inom vuxensjukvården. Vidare ville de 
unga vuxna att vårdgivarna skulle involvera dem i egenvården under tonåren samt ansåg att 
deras astma fick otillräckligt stöd från vårdgivarna. 
I delstudie III undersöktes omhändertagandet av ungdomar och unga vuxna under 
överföring från barn- till vuxensjukvården. För att göra detta användes även information från 
svenska register över astmarelaterade köp av mediciner samt sjukvårdskontakt. Resultaten 
visade att sjukvårdskontakterna var färre än vad som rekommenderas och dessutom minskade 
efter överföringen till vuxensjukvården. Få ungdomar med astma hade regelbunden 
astmabehandling under överföringsprocessen. 
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I delstudie IV identifierades olika typer av astma från barndom till ung vuxen ålder och 
dessa typerna karakteriserades utifrån bland annat astmakontroll och svårighetsgrad. 
Resultaten visade att de som debuterar sent och de som har ihållande astma har liknande 
nivåer av astmakontroll och svårighetsgrad under tonåren och ung vuxen ålder. 
Sammanfattningsvis tydde resultaten på att astma var vanligt bland ungdomar och unga 
vuxna. Ungefär hälften hade en okontrollerad astma under tonåren, vilket var vanligare bland 
kvinnor än män. Genom att identifiera och karakterisera olika typer av astma kan 
omhändertagandet och behandlingen av astma individualiseras. Omhändertagandet av unga 
med astma sker inte enligt riktlinjerna för astma; därför är det en viktig uppgift för sjukvården 
att identifiera de ungdomar som behöver fortsatt sjukvård i överföringsprocessen för att 
förhindra att sjukdomen försämras.
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